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ABSTRACT 
Background: A human ribosomal protein L9 (RPL9) encodes a protein that is a component 
of the 60S subunit. RPL9 is located on chromosome 4p14 and is approximately 5.5 kb in 
length and contains 8 exons. The message for human RPL9 is 712 nucleotides long. Some of 
the functions of RPL9 documented so far include the crucial involvement of the gene product 
in cell proliferation and protein biosynthesis. Lipoic acid synthetase (LIAS) is a 1.73 kb gene 
also located at chromosome 4p14. Alternative splicing occurs at these locus and two 
transcript variants encoding distinct isoforms have been identified but in this study the results 
represents both isoforms together. The protein encoded by LIAS gene belongs to the biotin 
and lipoic acid synthetases family and localizes in the mitochondrion. Function of lipoic acid 
synthetase is not yet well documented. Some studies have attempted to characterise its 
function by looking at the biological pathways at which LIAS gene product plays a crucial 
role, for example the biosynthesis of alpha-lipoic acid. Alpha lipoic acid is a natural 
antioxidant and it is also naturally-occurring enzyme co-factor found in a number of multi-
enzyme complexes regulating oxidative metabolism.  
Motivation for study: RPL9 and LIAS were previously found to be mutated in CHO 
(Chinese Hamster Ovary) cell lines and these mutant lines had gained resistance to apoptosis. 
Aim: The main objective of this study was to evaluate the expression pattern of RPL9 and 
LIAS in lung cancer and to characterise their role in apoptosis and also to determine if the 
expression pattern of this genes varies between normal and diseased state of the tissue.  
Methods: In Situ hybridization, quantitative Real Time PCR, TUNEL and Bio-informatics 
have been employed in order to attain the objectives of this study.  
Results: In Situ hybridization showed that RPL9 localises in the cytoplasm and it is up-
regulated in lung cancer relative to normal lung. LIAS localises in the cytoplasm and it is 
also up-regulated in lung cancer. The expression of RPL9 was relatively higher than that of 
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LIAS determined by the intensity of localisation. Quantitative real time PCR confirmed the 
up-regulation of RPL9 and LIAS in lung cancer. RPL9 and LIAS were found to be up-
regulated 8 and 4 fold respectively in lung A549 lung adenocarcinoma relative to MRC5 
normal lung fibroblast cell lines. TUNEL showed the highest DNA fragmentation in 
adenocarcinoma, followed by squamous cell lung carcinoma then large cell lung carcinoma 
which is the same pattern observed in RPL9 and LIAS mRNA localisation by In Situ 
hybridization.  
To further characterise the role of RPL9 and LIAS in human, Bio-informatics tools were used 
and the results revealed that RPL9 is highly conserved through evolution, up-to 100 % 
identical to chimpanzee and 98 % to mouse. LIAS was found to be 91 % identical to rat and 
90 % identical to mouse. It has been documented that the rate of conservation of a gene in 
evolution is believed to be correlated with its biological importance and its number of 
protein–protein interactions.   
Conclusion: All these discoveries coupled with resistance to apoptosis of CHO cell line in 
which RPL9 and LIAS were found to be mutated following promoter-trap mutagenesis, 
strongly suggests that RPL9 might be playing a role in cell cycle and apoptosis. RPL9 has 
been highly conserved through evolution. Manipulation of this gene can lead to greater 
biological discoveries in cancer research and the elevated expression of RPL9 can be used as 
a molecular marker for early detection of cancer. 
 
 
 
 
 
   vi 
 
DEDICATIONS 
 
I dedicate this work to my daughter Rorisang whom I left when she was very young to 
pursue this degree and to my mother who utterly stood in and not replaced me but helped 
raise my child with so much love.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   vii 
 
ACKNOWLEDGEMENTS 
 
 My heartfelt admiration and gratitude goes to my supervisors Prof Dlamini and 
Prof Hosie for encouraging and supporting me throughout the research. 
 
 To Prof D.J.G Rees from the department of Biochemistry, University of the 
Western Cape for granting the project making this study possible 
 
 To the National Health Laboratory Service, department of Pathology for 
providing with the tissue sections. 
 
 To Dr. M Ntwasa from the School of Molecular and Cell Biology for the use of 
the Zeiss microscope camera and AxioCam software. 
 
 To my colleagues for their support and making it such a pleasant time. I am 
utterly grateful to Raymond Motadi for his support in all my experiments that 
required cultured cells making this study possible. 
 
 To my family and friends, mainly my mother and my father who stood by me 
encouraging me to follow my dreams. My sincere gratitude to my two brothers 
and three sisters who made my daughter’s stay at home a warm and fun place to 
be. 
 
   viii 
 
 To the University of the Witwatersrand, National Research Foundation (NRF), 
Medical Research Council (MRC), University Research Council (URC) for 
funding provided making this study possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   ix 
 
TABLE OF CONTENTS 
Declaration          ii 
Meetings          iii 
Abstract          iv 
Dedications          vi 
Acknowledgements         vii 
Table of contents         ix 
List of figures          xv 
Abbreviations          xvii 
 
1. Literature Review         1 
1.1. Apoptosis          1            
1.1.1. Two major apoptosis pathways      2 
1.1.1.1. Extrinsic/Death Receptor pathway     2 
1.1.1.1.1. Fas signalling pathway     3 
1.1.1.1.2. TNFR signalling pathway     5 
1.1.1.1.3. TRAIL signalling pathway    5 
   1.1.1.2. Intrinsic- mitochondria activated- pathway    7 
1.1.2. Genetic regulation of apoptosis by tumour suppressor genes  9 
1.1.2.1. P53        9 
1.1.2.2. Retinoblastoma (Rb)      9 
1.2. Cell cycle          12 
   x 
 
1.2.1. Regulation of cell cycle      12 
1.2.1.1. Cyclin dependent kinases     12 
1.3. Cancer          13 
1.4. Lung Cancer         15 
1.4.1. Pathophysiology       16 
1.4.1.1. SCLC        16 
1.4.1.2. NSCLC       17 
1.4.1.2.1. Squamous Cell Carcinoma    17 
1.4.1.2.2. Adenocarcinoma     18 
1.4.1.2.3. Large-cell carcinoma    19 
1.4.2. Prognosis         19 
1.4.3. Aetiology        22 
1.4.3.1. Tobacco smoking      22 
1.4.3.2. Asbestos       23 
1.4.3.3. Genetic alterations      24 
1.4.3.3.1. Oncogenes      24 
1.4.3.3.1.1. Ras     24 
1.4.3.3.1.2. c-Myc     25 
1.4.3.3.1.3. EGFR     26 
1.4.3.3.2. Tumour suppressor genes    27 
1.4.3.3.2.1. P53     27 
1.4.3.3.2.2. Retinoblastoma (Rb) protein  28 
1.4.3.3.2.3. Tumour suppressor genes at  
   xi 
 
       chromosome region 3p   28 
1.4.3.3.3. Apoptosis genes    29 
1.4.3.3.3.1. Fas    29 
1.4.3.3.3.2. BCL-2    29 
1.4.4. Lung cancer and apoptosis      30 
1.5. Lipoic Acid Synthetase       31       
 1.5.1. LIAS and apoptosis      33 
1.6. Ribosomal Protein L9        33 
1.6.1. RPL9 and apoptosis        34 
Main Objective         35 
Rationale          35 
2. Materials and Methods        36 
2.1. Sample collection        36 
2.2. Preparation of Competent Cells       36 
2.3. In Situ Hybridization        37 
2.3.1. RNA isolation        38 
2.3.2. Formaldehyde agarose gel electrophoresis    40 
2.3.3. Reverse transcription- Polymerase Chain Reaction   41 
2.3.4. Primers design and synthesis      42 
2.3.5. Polymerase Chain Reaction      43 
2.3.6. Agarose gel electrophoresis for DNA     44 
   xii 
 
2.3.7. Cloning         45 
  2.3.7.1 Ligation       45 
2.3.7.2. Transformation       46 
2.3.8. Colony Polymerase Chain Reaction     47 
2.3.9. Plasmid DNA extraction      47 
2.3.10. Sequencing        49 
2.3.11. Linearization of clones      49 
2.3.12. Purification of DNA from Agarose Gel    50 
2.3.13. Digoxygenin (DIG) Probe Labelling     52 
2.3.14. Estimation of probe concentration     54 
2.3.15. Procedure for In Situ Hybridization     56 
2.3.15.1. Pre-hybridization treatment of sections   56 
2.3.15.2. Hybridization          57                            
2.3.15.3. Post-Hybridization       58 
2.3.15.3.1. Colorimetric Detection    58 
2.3.15.3.2. Fluorescent Detection    59 
2.4. Real Time Polymerase Chain Reaction      60 
2.4.1. Optimisation of primers      63 
2.4.2. Standard curve generation      64 
2.4.3. Relative quantitative Real Time Polymerase Chain Reaction  66 
2.5. TUNEL          67 
2.5.1. Controls        68 
2.6. Bioinformatics         69 
   xiii 
 
2.6.1. Gene Conservation       69 
3. Results          70 
3.1. Expression of LIAS and RPL9 in human lung cancer    70 
3.1.1. In Situ hybridization       70 
3.1.1.1. RNA extraction      70 
3.1.1.2. Polymerase Chain Reaction     70 
3.1.1.3. Cloning of RPL9 and LIAS into p-GEM T Easy  72 
3.1.1.4. Colony PCR       72 
3.1.1.5. Plasmid DNA extraction and sequencing   73 
3.1.1.6. Linearisation of clones and DIG labeling of probes  76 
3.1.1.7. Ribosomal Protein L9 and Lipoic Acid Synthetase    
genes localisation      77 
3.2. Real Time Polymerase Chain Reaction      86 
3.2.1. Assessment of assay efficiency and optimisation using standard  
curves         86 
3.2.2. Melting curves for RPL9 and LIAS     90 
3.2.3. Relative Quantitative Real Time Polymerase reaction of RPL9  
and LIAS expression normalised against unit mass   93 
3.3. TUNEL          97 
3.4. Bioinformatics         100 
3.4.1. Gene Conservation       100 
3.4.1.1. Lipoic Acid Synthetase CLUSTALW 2.0.3 multiple  
sequence alignment      100 
   xiv 
 
3.4.1.2. Ribosomal Protein L9 CLUSTALW 2.0.3 multiple  
sequence alignment      102 
3.4.2. Bioinformatics gene Interaction      104 
 
4. Discussion          106 
4.1. Lung cancer         106 
4.2. In Situ Hybridization        107 
4.3. Real Time Polymerase Chain Reaction      108 
4.4. Bioinformatics         110 
4.5. TUNEL          112 
 
5. Conclusion        114 
6. References        116 
Appendix 1: Reagents and Solutions      129 
    
 
LIST OF FIGURES 
Figure 1-1. Models for Apoptosis signalling Death Factors 
Figure 1-2. Intrinsic apoptotic pathway triggered by p53 
Figure 1-3. Activation of p21 by p53 in response to DNA damage 
Figure 1-4. Cell cycle arrest by p35 
Figure 3-1: Polymerase Chain Reaction 
Figure 3-2: Colony Polymerase Chain Reaction 
   xv 
 
Figure 3-3. Sequence alignment of RPL9 and LIAS genes 
Figure 3-4: Plasmid DNA extraction 
Figure 3-5: Restriction digestion RPL9 clone 
Figure 3-6: Restriction digestion of LIAS clone 
Figure 3-7: Localisation of RPL9 mRNA in Squamous Cell Lung Carcinoma  
Figure 3-8: Localisation of RPL9 mRNA in Small Cell Lung Carcinoma 
Figure 3-9: Localisation of RPL9 mRNA in Large Cell Lung Carcinoma 
Figure 3-10: Localisation of RPL9 mRNA in Lung Adenocarcinoma 
Figure 3-11: Localisation of LIAS in Squamous Cell Lung Carcinoma 
Figure 3-12: Localisation of LIAS mRNA in Lung Adenocarcinoma 
Figure 3-13: Localisation of LIAS mRNA in Small Cell Lung Carcinoma 
Figure 3-14: RPL9 standard curve to assess the efficiency of the reaction assay. 
Figure 3-15: LIAS standard curve generated to assess the efficiency of the reaction assay 
Figure 3-16: Annealing temperature optimization and melting curve to analyse the 
specificity of RPL9 primers 
Figure3-17: Annealing temperature optimization and melting curve to analyse the 
specificity of LIAS primers 
Figure 3-18: Quantification curve for LIAS 
Figure 3-19: Quantification curve for RPL9 
Figure 3-20: Apoptosis detection by TUNEL in lung cancer 
Figure 3-21: CLUSTALW 2.0.3 multiple sequence alignment for LIAS 
Figure 3-22: CLUSTALW 2.0.3 multiple sequence alignment for RPL9 
 
   xvi 
 
ABBREVIATIONS 
%    - Percent   
°C   – Degree Celsius 
µ   - micro   
aa   - Amino acid 
A260/280  - Absorbance at 260 nm or 280 nm 
A549   – Human Epithelial Cell Lung Carcinoma Cell Line 
Acinis   – Apoptotic Chromatin Condensation Inducer in the Nucleus 
ADP   – Adenosine Diphosphate 
AP  - Alkaline phosphatase  
Apaf   – Apoptosis Activating Factor 
APO  - Apoptosis-Mediating Surface Antigen Fas 
Arg  - Arginine 
ATP   – Adenosine Triphosphate 
ATPase - Adenosine Triphosphate 
Β  - Beta 
Bad   – Bcl-2-Antagonist of Cell Death Protein 
Bax   – Bcl-Associated X Protein 
BCIP   – 5-Bromo-4-Chloro-3-Indolyl Phosphate 
Bcl   – B-Cell Lymphoma/Leukaemia 
BH   – Bcl-2 Homology 
Bid   – Bcl-2-Interacting Domain Death Agonist 
bp   – base pair 
   xvii
 
BSA   – Bovine Serum Albumin 
CaCL2  – Calcium Chloride 
CAD  - Caspase-Activated DNase (ADP-Ribose) 
CARD  - Caspase Recruitment Domain 
Caspases  – Cysteinyl Aspartate-Specific Proteases 
Cdc  - Cell Division Cycle 
cDNA   – complementary Deoxy-ribonucleic Acid 
CDK  - Cyclin-Dependent Kinase 
CDK4   - Cyclin-Dependent Kinase 4 
CDKI   - Cyclin-Dependent Kinase Inhibitors 
cm
3
   – Cubis Centimetre 
CoA  - Coenzyme A 
cRNA   – complementary – RiboNucleic Acid 
CT   – Threshold Cycle 
Da   – Daltons  
dATP   - Deoxyadenine Triphosphate 
dCTP   - Deoxyvytosine Triphosphate   
DD   – Death Domain 
DDT   – dithiotretiol 
DED   – Death Effector Domain 
DEPC   – Diethyl Pyrocarbonate 
DF   – Dilution Factor 
dGTP   - Deoxyguanine Triphosphate  
   xviii 
 
DIG   – Digoxigenin 
DISC   – Death Inducing Signalling Complex 
DMEM - Dulbecco’s Modified Eagle Media 
DNA   – Deoxy-ribonucleic Acid 
DNase  – Deoxyribonuclease 
dNTP   – Deoxyribonucleotide Triphosphate 
DcR   – Decoy Receptor 
DR   – Death Receptor 
ds   – Double Stranded 
dsDNA  – double stranded Deoxy-ribonucleic Acid 
dTTP  - Deoxythymine Triphosphate 
dUTP   – Deoxyuridine Triphosphate 
E   – Efficiency 
EDTA  – Ethylenediamine Tetra Acetic Acid 
EGFR   – Epidermal Growth Factor Receptor 
FADD  – Fas-Associated Death Domain 
Fas   – Fibroblast-Associated 
FasL   – Fibroblast-Associated Ligand 
FITC   – Fluorescein Isothiocyanate 
Fig   – figure  
g   – Gram  
H&E   – Haematoxylin and Eosin 
H2O   – Water  
   xix 
 
HCl   – Hydrochloric Acid 
H&E  - Haematoxylin and Eosin 
Hr   – hour  
Hrs   – hours 
I  - One 
IAP   - Inhibitors of Apoptosis Protein 
Ig  - Immunoglobulin 
II   - Two 
III  - Three 
IPTG   – Isopropyl-β-D-Thiogalactopyranoside 
IV   - Four 
Κ  - Kappa 
k   – Kilo 
KAc   - Potassium Acetate 
l   – Litre  
L  - Litre 
LB   – Luria Bertani 
LIAS   – Lipoic Acid Synthetase 
LiCL   – Lithium Chloride 
m   – milli  
M   – Molar 
mg  - Milligram 
MgCl2  – Magnesium Chloride 
   xx 
 
min   – minutes  
ml   – millilitres  
MnCl2  – Manganese Chloride 
MOPS  - 3-[N-Morpholino] Propane Sulfonic Acid 
mRNA  – messenger Ribonucleic Acid 
NaCl   – Sodium Chloride 
NADH  – Nicotinamide Adenine Dinucleotide Hydrogenase 
NaOH  - Sodium Hydroxide 
NBT   – Nitroblue Tetrazolium 
NCBI   – National Centre for Biomedical Information 
NF   – Nuclear Factor 
nm  - Nanometre 
p53  - Tumour suppressor protein 53 
PBS   – Phosphate Buffer Saline 
PCR   – Polymerase Chain Reaction 
PFA   – Paraformaldehyde 
pH  - Hydrogen Ion Concentration  
qRT-PCR – quantitative Real Time Polymerase Chain Reaction 
Raf  - Riboflacin-Aldehyde Forming Enzyme 
Rb   – Retinoblastoma  
RNA   – Ribonucleic Acid 
RNase  – Ribonuclease  
RPL9   – Ribosomal Protein L9 
   xxi 
 
RPM   – Revolutions per Minute 
RT   – Room Temperature 
RT-PCR  – Real Time Polymerase Chain Reaction 
S  - Second 
S  - DNA Synthesis Phase 
SDS  - Sodium Dodecyl Sulphate 
sdH2O  – Sterile Distilled Water 
SSC   – Sodium Chloride and Sodium Citrate 
TBE   – Tris-Borate/EDTA 
TBS   – Tris Buffer Saline 
TE   – Tris-HCL/EDTA 
Tm   – Melting Temperature 
TNB   – Tri-Sodium Blocking 
TNF   – Tumour Necrosis Factor 
TNFR   – TNF Receptor 
TRADD  – TNFR-I-Associated Death Domain  
TRAIL  – TNF-Related Apoptosis Inducing Ligand 
Tris   – Tris (Hydroxymethyl) Aminomethane 
Tween 20  – Polyethylene Sorbitan Monolaurat 
TYM   – Trptone Yeast Extract MgCL2 
UV   – Ultra Violet 
VEGF  - Vascular Endothelial Growth Factor 
v/v  - Volume/Volume 
   xxii
 
WHO   – World Health Organisation 
w/v  - Weight/Volume 
α   – Alpha 
β   – Beta  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1 
 
1. Literature Review 
1.1. Apoptosis 
For every cell there is time to live and time to die. There are two major mechanisms by 
which cells die, apoptosis and necrosis (Kroemer, et al., 2009). In necrosis cell death is 
uncontrollable and lead to lysis of cells, inflammatory responses and detrimental health 
problems. Contrary to necrosis, apoptosis is a genetically controlled mechanism essential 
for the maintenance of tissue homeostasis, proper development and the elimination of 
unwanted cells by allowing a cell to self-degrade hence is also called programmed cell 
death. Apoptosis is shown to occur in a predictable manner during development and also 
to serve as a major mechanism for removal of unwanted and potentially dangerous cells 
such as virus-infected cells, self-reactive lymphocytes, tumour cells, aged cells and cells 
with DNA damage that cannot be repaired (Lockshin and Zakeri, 2001). 
 
Upon receiving specific stimuli instructing the cell to undergo apoptosis, a number of 
morphological and biochemical changes occur in the cell, including cell shrinkage, 
chromatin condensation, nuclear fragmentation, membrane blebbing and loss of adhesion 
(Kroemer et al., 2009; Kerr et al., 1972). A family of proteins known as caspases are 
activated in early stages of apoptosis. These proteins cleave key cellular substrates that 
are required for normal cellular functioning such as structural proteins and nuclear 
proteins. The caspases can also activate other degradative enzymes such as DNases, 
which begin to cleave DNA in the nucleus. The result of these biochemical changes is 
appearance of morphological changes in the cell. Typically cytoplasm begins to shrink. 
Nuclear condense following the breakdown of chromatin and nuclear structural proteins. 
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Cells continue to shrink, packaging themselves in a form that allows for recognition and 
clearance by macrophages. (Baehrecke, 2002; Martin et al., 1995).  
 
1.1.1. Two major apoptosis pathways 
Although cell death can be triggered by vast array of stimuli, the manner by which all 
apoptotic signals engage the cell death machinery falls under two broad categories, one 
beginning at the level of cell surface, death receptor (the extrinsic pathway), the other is 
mediated by mitochondrial (the intrinsic pathway) (Kiechle and Zhang, 2002). 
 
1.1.1.1. Extrinsic/Death Receptor pathway 
In the death receptor pathway, apoptosis induction involves the engagement of a set of 
ligands and their corresponding receptors and then transmission of the apoptotic signal in 
the cytoplasm by a number of caspases (Yusuke et al., 2010). There are a number of 
ligand-receptor systems and target caspases involved in apoptosis. These death-inducing 
receptors belong to the tumour necrosis factor (TNF) superfamily. The most well 
characterised death receptors are Fas, TNF-R1, TRAIL-R1 and TRAIL-R2 receptors, all 
of which are characterised by a cysteine-rich extracellular “death domain” (Ashkenazi 
and Dixit, 2008). The ligands that activate these receptors are structurally related 
molecules that belong to the TNF genes superfamily; fas ligand (FasL) bind to Fas, TNFα 
and lymphotoxinα bind to TNF-R1 and TRAIL bind to TRAIL-R1 and TRAIL-R2 (Igney 
and Krammer, 2002; Debatin and Krammer, 2004). 
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When a ligand binds to the death receptor, the receptor becomes trimerised and activated. 
The activated receptor recruits a death domain containing adaptor and a pro-caspase 8 
molecule through protein-protein interaction to form a death inducing signalling complex 
(DISC). Fas associated death domain (FADD) is directly recruited into the DISC during 
Fas-mediated apoptosis, while TNF-induced apoptosis involves both FADD and TRADD 
(TNF Receptor-Associated Death Domain) (Kischkel, et al., 2000). Recruitment of pro-
caspase 8 to the DISC activates caspase 8 by oligomerisation-induced autocatalytic 
processing which results in activation of downstream caspases, such as caspase 3, 6 and 
7, and induction of apoptosis (Ashkenazi and Dixit, 1998; Ashkenazi and Dixit, 2008). 
 
1.1.1.1.1. Fas signalling pathway 
Fas, a cell surface receptor plays a crucial role in apoptosis signalling in many cell types. 
Fas is expressed on the surface of cell membranes in a variety of normal tissue cells and 
malignant cells including lung cancer cells whereas the expression of FasL is restricted to 
the cells within the immune system, such as activated T cells and natural killer cells. Fas 
is ubiquitously expressed in various tissues with abundant expression in the thymus, liver, 
heart and kidney. Fas is also predominantly expressed in activated T lymphocytes and 
natural killer cells (Kitaura et al., 2002). This receptor interacts with its natural ligand 
(FasL), a member of the tumour necrosis factor superfamily, to initiates the death signal 
cascades which results in apoptotic cell death. Upon FasL binding, juxtaposition of the 
Death Domain (DD) allows interaction with the DD containing adaptor protein FADD. 
FADD is a 26 kDa cytoplasmic protein that contain a C-terminal DD and a homologous 
Death Effector Domain (DED). Fas ligation results in DISC assembly commencing 
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within minutes of ligand binding and localizing initially FADD and then caspase 8 to the 
receptor complex. Caspase 8 has two C-terminal DED that display homology to and can 
interact with DED of FADD (Kischkel et al., 2000). Caspase 8 is produced as a zymogen, 
activated first by removal of a pro-domain then by limited cleavage at an aspartate 
residue to separate the large 20 kDa active protease subunit from the smaller 10 kDa 
subunit. This caspase can process downstream pro-caspases as well as its own procaspase 
precursor. Caspase activation proceeds in a hierarchical manner until activation of the 
executor caspases such as caspase 3, 6 and 7, result in apoptosis. The effector caspases 
are responsible for proteolytic cleavage of various cellular substances leading to the 
distinctive DNA fragmentation that marks apoptosis (Salvesen and Dixit, 1999).  
Reduced expression of Fas and/or increased expression of FasL have been detected in 
many types of human cancers including lung cancer and appear to be a feature of 
malignant phenotype suggesting that the Fas/FasL system play an important role in 
cancer formation. There is strong evidence demonstrating that decreased expression of 
Fas may protect transformed cells from elimination by anti-tumour immune response, but 
elevated expression of FasL may increase the ability of tumour cells to counterattack the 
immune system by killing Fas sensitive lymphocytes and therefore contribute to cancer 
development. Since FasL expressed on T-lymphocytes can induce apoptosis in Fas-
expressing lung cancer cells, the Fas/FasL system plays an important role in the cell-
mediated cytotoxic reactions against lung cancer. Commonly used chemotherapy drugs 
have been shown to induce Fas expression on lung cancer cells and apoptosis of lung 
cancer cells (Volm and Rittgen, 2000).  
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1.1.1.1.2. TNFR signalling pathway 
In contrast to Fas, TNF-R1 only signals for cell death in certain circumstances, for 
example, when protein synthesis is blocked. In most scenarios, TNF-R1 instead induces 
the transcription and activation of inflammatory genes suggesting that TNF-R1 signalling 
provides a mechanism to suppress the apoptotic stimulus (Kischkel, et al., 2000). 
1.1.1.1.3. TRAIL signalling pathway 
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential 
anticancer drug that promotes apoptosis specifically in tumour cells. TRAIL seems to 
induce apoptosis only in cancer cells and not in normal tissue and this includes lung 
cancer cells (Yanase et al., 2005; Ashkenazi et al., 1999). TRAIL triggers apoptosis 
through interaction with death receptor DR4 and DR5. In contrast to other members of 
TNF superfamily, TRAIL is expressed constitutively in many tissues which suggest the 
existence of physiological mechanism that can protect many normal cell types from 
induction of apoptosis specifically by TRAIL. One of such mechanism may involve 
expression of antagonistic decoy receptors that can compete with TRAIL-R1 (DR4) and 
TRAIL-R2 (DR5) for ligand binding; TRAIL binds with 3 such decoys: TRAIL-R3 
(DcR1), TRAIL-R4 (DcR2) and TRAIL-R5 (osteoprotegerin) (Yusuke et al., 2010; 
Ashkenazi et al., 1999).  
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Figure 1-1. Models for Apoptosis signalling Death Factors. Binding of FasL to Fas induces 
trimerisation of Fas receptor, which recruits caspase-8 via FADD adaptor. Trimerised TNFR1 due to TNF 
binding recruits TRADD, which then recruits FADD in one pathway to activate caspase-8. In another 
pathway, RIP binds to TRADD and transduces an apoptotic signal through the death domain.   
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1.1.1.2. Intrinsic- mitochondria activated- pathway 
The intrinsic cell death pathway is initiated as a response to multiple stress signals and 
depends on alterations involving the mitochondria ultimately leading to mitochondrial 
dysfunction. The Bcl-2 family members play a vital role in intrinsic pathway.  The Bcl-2 
family of proteins contains both the pro- and anti-apoptotic molecules and the ratio 
between two subsets help determine the susceptibility of a cell signal (Vo and Letai, 
2010). Bcl-2 family members possess up to four conserved Bcl-2 homology (BH) 
domains designated BH1, BH2, BH3 and BH4. Many of the anti-apoptotic members 
display sequences conserved in all four domains while the pro-apoptotic members display 
less sequence conservation of the BH4 domain. Pro- and anti-apoptotic Bcl-2 members 
localise to separate subcellular compartments in the absence of a death signal. Anti-
apoptotic members are intergral membrane proteins found in the mitochondria, 
endoplasmic reticulum or nuclear membrane (Hockenbery 2010; Hsu et al., 1997). 
Triggering of mitochondrial cell death pathway results in release of pro-apoptotic 
proteins from the mitochondrial intermembrane space into the cytosol. Signals from the 
internal sensors are propagated to the mitochondria via pro-apoptotic Bcl-2 subfamily 
members (BH3 only), such as Bid, to oligomerize Bax and Bak, which are outer 
mitochondrial membrane proteins that promote the release of cytochrome c. Cytochrome 
c oligomerizes Apaf1 and recruits pro-caspase-9 (forming the apoptosome), which results 
in proteolytic conversion of pro-caspase-9 to an active enzyme. Caspase-9 then converts 
pro-caspase-3 to its active form, which, with other executioner caspases, such as caspase-
7 stimulate the apoptotic signal pathway (Saelens et al., 2004; Gross et al., 1998). 
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Figure 1-2. Intrinsic apoptotic pathway triggered by p53. The intrinsic apoptotic pathway is 
initiated by internal sensors such as p53 that monitor cellular stresses such as viral infection via activation 
of BH3 domain−only members of the Bcl-2 family. Activated BH3-only proteins are thought to mediate the 
assembly of pro-apoptotic members of the Bcl-2 family resulting in the release of factors such as 
cytochrome c which after entry into the cytosol stimulates the formation of a complex called apoptosome, 
leading to caspase-9 activity ant then resulting stimulation of apoptotic signal pathway (McCabe and 
Dlamini, 2005). 
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1.1.2. Genetic regulation of apoptosis by tumour suppressor genes 
1.1.2.1. P53 
P53 is a tumour suppressor gene which monitors stress and directs the cell towards an 
appropriate response. Upon activation, p53 induces either G1 cell cycle arrest or 
apoptosis. For these reason, p53 is called “the guardian of the genome” (Levie, 1997; 
Rusan and Peifer, 2008, Tommasi et al., 2008).  The p53 protein prevents a cell from 
completing the cell cycle if its DNA is damaged or the cell has suffered other types of 
damage. It does this by binding to a transcriptional factor called E2F. This prevents E2F 
from binding to the promoters of proto-oncogenes such as c-fos. Transcription c-fos is 
needed for mitosis, so blocking the transcription factor needed to turn on these genes 
prevents cell division. If the damage is minor, p53 halts the cell cycle hence cell division 
until the damage is repaired. If the damage is major and cannot be repaired, p53 triggers 
the cell to commit suicide by apoptosis as illustrated in Fig 1-3. 
P53 also prevent a cell from completing the cycle in response to DNA damage by 
inducing expression of a series of cdk inhibitors, p21, p27, and p57 which function to 
maintain retinoblastoma protein (Rb) in its unphosphorylated state even in the face of 
mitogenic stimulation. This control is released once the cell has effectively repaired its 
damaged DNA (Colman et al., 2000) 
 
1.1.2.2. Retinoblastoma (Rb) 
Retinoblastoma protein was the first protein to be identified as a tumour suppressor in 
humans in a study that demonstrated that loss of function of the protein leads to 
retinoblastoma in children (Friend et al., 1986). Additionally pRb’s functional loss has 
   10 
 
also been implicated in other malignancies such as ovarian cancer (Armes et al., 2005, Li 
et al., 2007d, Masamha and Benbrook, 2009), head and neck squamous cell carcinoma 
(Golam Sabbir et al., 2006) and soft-tissue sarcoma (Polsky et al., 2006, Pereira et al., 
2009). These suggest that pRb loss plays a pivotal role in cancer progression. 
 
 
Figure 1-3. Activation of p21 by p53 in response to DNA damage. In response to DNA 
damage, p53 activate p21 to inhibit the release of transcription factor E2F from Rb by cyclin/cdk2. This 
stops the expression of enzymes essential for DNA replication and thus halt the cell from continuing with 
cell cycle. This allows time for DNA to be repaired and failure to repair DNA will lead to cell death by 
apoptosis triggered by p53. http://www.nature.com/nrc/journal/v6/n1/full/nrc1780.html 
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Figure 1-4. Cell cycle arrest by p35.  P53 induce cell cycle arrest to allow time for DNA to be 
repaired. If the damage is too severe and cannot be repaired, then p53 triggers cell death by apoptosis. 
(McCabe and Dlamini, 2005) 
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1.2. Cell cycle 
The cell cycle is the set of events that are responsible for duplication of the cell. 
Eukaryotic cell cycle consists of the two most important phases, S-phase and the M-
phase. At S-phase, DNA is replicated and proteins are synthesized. During this stage 
every double-helical DNA molecule is duplicated, making two strands of DNA that are 
exactly identical. At the M-phase the replicated material is segregated into two daughter 
nuclei. Between S and M phase there are two gaps, G1 prior to S-phase and G2 prior to 
M-phase. G1 is the growth phase of the cell and preparation of chromosomes for 
replication occur at these phase. G2 is the preparation phase for mitosis. Following M-
phase is the cytokinesis phase.The actual cell division takes place in the cytokinesis and 
is the phase when the physical division of the cell's cytoplasm into two daughter cells 
takes place. Each daughter cell receives about half the contents of the original cell 
including one copy of the DNA (Nurse, 1994; Manuel and Sergio, 1997). 
 
1.2.1. Regulation of cell cycle 
1.2.1.1. Cyclin dependent kinases 
To allow for normal growth and development, the passage of the cell through the cell 
cycle is regulated by highly coordinated and tightly controlled checkpoints at G1/S 
transition and G2/M transition. These processes make use of cytoplasmic proteins. 
Among the main players are cyclins and cyclin-dependent kinases (Cdk). Cyclins include 
a G1-phase cyclin (cyclin D), S-phase cyclin (cyclin E and D) and mitotic cyclins (cyclin 
A and B). In animal cell at least eight (cdk1-cdk8) cyclin dependent kinases have been 
discovered although only M-phase cdk1, G1 cdk4 and cdk6, and S-phase cdk2 play a role 
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in cell cycle regulation. (Nigg, 1995). Cdk levels in the cell remain fairly stable, but each 
must bind the appropriate cyclin, whose levels fluctuate with the stages of the cell, in 
order to be activated. A cyclin joins with an appropriate cdk to form a complex. If for 
some reason the cell detects some problem with a continuation of a cycle, the activation 
of a cyclin-cdk complex is not completed. If no defect is detected, the cyclin-cdk 
complex is activated by phosphorylation and these lead to the activation of a transcription 
factor by the removal of an inhibitor of the transcription factor. The transcription factor 
then turns on the transcription of specific genes necessary for the next cell cycle step 
(Manuel and Sergio, 1997).  
 
1.3. Cancer 
Cell cycle is strictly regulated by mechanisms described previously in order to maintain 
the tissue homeostasis. Failure of these regulatory mechanisms can lead to uncontrolled 
proliferation of cells leading to formation of tumours. Tumours can either be non-
cancerous (benign) or cancerous (malignant). Benign tumours may grow causing 
discomfort due to bleeding, but they do not spread to other parts of the body and 
generally are not life threatening. Malignant tumours spread into other areas of the body 
and destroy normal tissue. This uncontrolled proliferation of cells that tend to invade 
surrounding tissues and metastasize to other organs is termed cancer (De Stefani et al., 
2005). 
A number of factors are involved in cancer development, among them is age, 
carcinogens, genetic make-up and day-to-day environment. These factors lead to 
accumulation of genetic mutations that cause cells to be non-responsive to the regulatory 
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mechanisms. This includes: point mutations which cause amino acid substitutions, frame- 
shift mutations or mutations to stop codons which either trunscate or scramble it’s 
sequence. These mutations have two distinctive consequences, they allow the 
inappropriate expression or activation of genes, or conversely, they result in the 
functional activation of the gene or its protein product.  
Mutations with two basic functions are selected by cells developing cancer, mutations 
which increase the activity of a certain protein they code for; this class of genes are called 
oncogenes, or mutations which inactivate gene function in the case of genes classed as 
tumour suppressor genes. Oncogenes are involved in signalling pathways which stimulate 
proliferation, while most tumour suppressor genes code for proteins which normally act 
as checkpoints to cell proliferation or cell death (Ames et al., 1993; Armes et al., 2005). 
Chemical damage to DNA itself is not mutagenic, it requires proliferation. DNA 
replication and subsequent cell division is necessary to convert chemical damage to an 
inheritable change in DNA, which is defined or referred to as mutation (Ames et al., 
1993). To most effectively reduce the probability of mutations, the genome should be 
damage free before the onset of replication. To achieve this and to also ensure that a cell 
has all the nutritional support required for the synthesis of the new DNA strands, 
mammalian cells have devised elaborate checkpoints to prevent premature entry into the 
division cycle.  
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1.4. Lung Cancer 
Lung cancer is the global most important leading cause of cancer deaths (Wingo et al., 
1995) with wide geographic variations in risk. Tobacco smoking is the main cause of 
lung cancer with a positive linear relationship between the probability of getting the 
cancer and dose-response relationship (years and amount smoked). Lung cancer has a 
lower incidence than other types of cancers (breast, colon, prostate and cervical) but it is 
more lethal with a 5 year survival of less than 10% (Parkin et al., 2005). Like all cells of 
the body, lungs cells divide and reproduce at a controlled rate to repair worn-out or 
injured tissues and allow for normal growth. Lung cancer develops when cells inside the 
lungs multiply at an uncontrollable rate. As cancer cells break away from the primary 
(original) tumour in the lung and spread through the blood and lymph systems, they form 
secondary (metastatic) tumours. Lung cancer can spread to any organ in the body, e.g. 
brain, liver, etc. Most often secondary tumours will develop in the brain, bone, liver and 
bone marrow. Secondary tumours are referred to as metastatic lung cancer rather than 
brain or liver cancer to indicate that they are part of a single disease originating in the 
lungs and are not new cancers starting in these organs (De Stefani et al. 2005). Since 
previously more men than women were smoking, lung cancer used to be more prevalent 
in men than in women. But because currently just as many women as men are smoking, 
incidence of lung cancer in women is just as high as in men. This is due to the fact that, 
though there are other risk factors associated with the development of lung cancer, 
smoking is the major aetiological factor.  
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1.4.1. Pathophysiology 
Lung cancers are divided into two major groups, which make up more than 90% of all 
lung cancer cases; small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). SCLC as opposed to NSCLC is characterized by relatively high sensitivity to 
treatment with anticancer drugs and irradiation. The way non-small cell lung cancer 
spreads and its treatment is very different from that of small cell lung cancer. Sometimes 
a lung tumour contains more than one type of cancerous cell. Because of the different 
types of lung cancers and different ways they may respond to treatment, it is very 
important to identify the cell types so that the best treatment can be given. In addition to 
the two main types of lung cancer, other tumours can occur in the lung. Some of these are 
non-cancerous (benign). Most are slow-growing tumours that are called typical carcinoid 
tumours. They are generally cured by surgery. Although some typical carcinoid tumours 
can spread, they usually have a better prognosis than small cell or non-small cell lung 
cancer (Franklin, 2000). 
1.4.1.1. SCLC 
SCLC makes up about 20% to 25% of all lung cancer cases. The identified cells include 
oat cell, intermediate cell (cells which have many sides and are spindle shaped) and 
combined cell (small cell combined with other types of cancer). Small cell lung cancer is 
most often found in the bronchial submucosa and is more likely to have spread at the time 
of diagnosis than other types of lung cancer. Small cell lung cancer is separated from 
other cell types due to its rapid growth rate. Symptoms are of brief duration prior to 
diagnosis (Friedman et al., 1965)  
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1.4.1.2. NSCLC 
NSCLC is a heterogeneous aggregate of at least 3 distinct histologies of lung cancer 
including squamous carcinoma, adenocarcinoma, and large cell carcinoma. These 
histologies are often classified together because, when localized, all have the potential for 
cure with surgical resection. Systemic chemotherapy can produce objective partial 
responses and palliation of symptoms for short durations in patients with advanced 
disease. Local control can be achieved with radiation in a large number of patients with 
unresectable disease, but cure is seen only in a small minority of patients. At diagnosis, 
patients with NSCLC can be divided into 3 groups that reflect the extent of disease and 
treatment approach. The first group of patients has tumours that are surgically resectable. 
This is the group with the best prognosis, depending on a variety of tumour and host 
factors. Patients with resectable disease who have medical contraindications to surgery 
can be considered for curative radiation therapy. The second group includes patients with 
either locally or regionally advanced lung cancer who have a diverse natural history. This 
group is treated with radiation therapy or, more commonly, with radiation therapy in 
combination with chemotherapy or other therapy modalities. The final group of patients 
have distant metastases found at the time of diagnosis. This group can be treated with 
radiation therapy or chemotherapy for palliation of symptoms from the primary tumour 
(Albain et al, 1991). 
 
1.4.1.2.1. Squamous Cell Carcinoma 
Squamous cell carcinoma accounts for over 30% of lung cancers. Squamous cell 
carcinoma usually starts in the large bronchi and very often stays in the chest, without 
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spreading for longer periods of time than other types of lung cancer. Because of its 
central location and the tendency of these cells to exfoliate, squamous cell carcinoma can 
be detected on cytologic examination at an early stage. With time these tumours tend to 
cause bronchial obstruction and atelectasis or pneumonia. They also tend to remain 
localised. Of all the subtypes of NSCLC, the sguamous cell lung carcinoma has the 
strongest association with smoking. Pathologically, it is characterised by visible 
keratinisation with prominent desmosomes and intercellular bridges. Increased secretion 
of a parathyroid-like hormone in squamous cell lung carcinoma has led to this subtype’s 
association with hypercalcemia (Ihde, 1991)  
 
1.4.1.2.2. Adenocarcinoma 
Adenocarcinomas is the most common form of cancer worldwide accounting for 35% of 
all lung cancers and have cube or column-shaped cells. These tumours are often found 
along the outer edges of the lungs and under the lining of the bronchi. New studies are 
under way to examine reasons for the increase in the rate of adenocarcinoma (Franklin, 
2000). The increased rate of adenocarcinoma could be associated with increased smoking 
incidences because the tumours often originate from scars that contain entrapped 
bronchial epithelium which are mostly caused by smoking. Even with smoking cessation, 
the risk remains elevated because the injury incurred in the airways cannot be reversed 
(Damjanov, 1996) 
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1.4.1.2.3. Large-cell carcinoma 
This type of cancer accounts for about 10% - 15% of lung cancers. It may appear in any 
part of the lung, and it tends to grow and spread quickly resulting in a poor prognosis. 
Where a poorly differentiated tumour has none of the defining features of small cell lung 
carcinoma, squamous cell lung carcinoma or adenocarcinoma, it may be classified as 
large cell lung carcinoma: that is, where the cells of the lesion are not-columnar in shape, 
do not contain mucous, do not show squamous differentiation, and do not have 
neuroendocrine properties or small cell characteristics. Tumours tend to consist of large 
cells with abundant cytoplasm, large nuclei and prominent nucleoli and they may occur 
peripherally or centrally. Variants of large cell carcinoma include clear cell carcinoma, 
giant cell carcinoma and large cell neuroendocrine carcinoma (Ihde, 1991) 
 
1.4.2. Prognosis  
The most important prognosis factor in lung cancer is the stage of the disease. 
Determination of stage has important therapeutic and prognosis implications, hence 
careful initial diagnostic evaluation to define location and extent of primary and 
metastatic tumour involvement is critical for the appropriate care for the patient. The 
TNM staging system for lung cancer has been developed and it is important as it provides 
a consistent reproducible
 
description of the extent of anatomic involvement, consistency 
in patient treatments and it provides the basis of epidemiological and biological studies. 
This is achieved by defining the characteristics of primary
 
tumour (T), regional lymph 
node involvement (N), and metastasis
 
(M) (Table 1.1) (Mountain, 1997; Omar et al., 
1999). 
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TABLE 1.1: TNM staging of lung cancer 
 
Primary tumour (T) 
Tx Tumour proven by the presence of malignant cells in brochopulmonary secretions 
 but not visualised roentgenographically or bronchoscopically or any tumour that  
 cannot be assessed, as in pre-treatment staging 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤ 3.0 cm in greatest dimension, surrounded by lung or visceral pleura,  
 and without evidence of invasion to a lobar bronchus at bronchoscopy 
T2 Tumour > 3.0 cm in greatest dimension or tumour of any size that either invades 
 the visceral pleura or has associated atelectasis or obstructive pneumonitis  
 extending to the hilar region (but involving less than the entire lung). At  
 bronchoscopy, the proximal extend of demonstrate tumour must be within 
 a lobar bronchus or at least 2.0 cm distal to the carina. 
T3 Tumour of any size with a direct extension into the chest wall (including superior  
 sulcus tumours), diaphragm or mediastinal pleura or pericardium without
 involving the heart, great vessels, trachea, oesophagus, or vertebral body; or  
 tumour in the bronchus within 2 cm of, but not involving the carina. 
T4 Tumour of any size with invasion of the mediastinum or involving the heart,  
 great vessels, trachea, oesophagus, vertebral body, or carina; or presence of  
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 malignant pleural effusion. 
 
Regional lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed  
N0 No demonstrable metastasis to regional lymph nodes 
N1 Metastasis to lymph nodes in the epibronchial and/or ipsilateral hilar region,  
 including direct extension. 
N2 Metastasis to ipsilateral mediastinal and subcarinal lymph nodes. 
N3 Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or 
 contralateral scalene, or supraclavicular lymph nodes 
 
 
Distant metastasis (M) 
Mx Distant metastasis cannot be assessed  
M0 No distant metastasis 
M1 Distant metastasis 
 
Stage grouping 
Occult carcinoma Tx  N0  M0 
Stage 0  Tis  N0  M0 
Stage 1A  T1  N0  M0 
Stage 1B  T2  N0  M0 
Stage IIA  T1  N1  M0 
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Stage IIB  T2  N1  M0 
   T3  N0  M0 
Stage IIIA  T3  N1  M0 
   T1-3  N2  M0 
Stage IIIB  Any T  N3  M0 
   T4  Any N  M0 
Stage IV  Any T  Any N  M1 
 
Omar et al., 1999  
 
1.4.3. Aetiology 
Lung cancer has a multifactorial aetiology and is a complex multi-step process. epidemic 
of lung cancer is directly attributed to cigarette smoking and there needs to be major 
efforts to prevent initiation and aid with cessation of smoking. Recently it has been clear 
that smoking leads to persistent genetic damage of the respiratory tract which implicates 
smoking as a core risk factor for the development of lung cancer (Wynder and Graham, 
1950) 
 
1.4.3.1. Tobacco smoking 
There has been overwhelming evidence that the epidemic of lung cancer is directly 
attributable to tobacco smoking (Doll and Hill, 1950; Wynder and Graham, 1950). 
Experimental studies have shown that painting of rabbit skin with cigarette tar induced 
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cancers, and some of the carcinogens present in tobacco smoke had been identified (Doll, 
1998) 
Tobacco smoking is a major risk factor of lung cancer with a contribution of 80-85% of 
lung cancer cases. Approximately one in ten lifetime smokers develop lung cancer 
suggesting individual differences in susceptibly to tobacco smoke. Genetic susceptibility 
to lung cancer may in part be determined by inter-individual variations in the genetic 
factors associated with cigarette smoking. Molecular biology has led growing interest in 
investigation of biological markers, which may increase/decrease predisposition to 
smoking–related carcinogenesis. Genetic differences are known for substances in tobacco 
smoke absorption, their metabolism and for their interactions with receptors (Kiyohara et 
al., 2002).   
Tobacco smoke contains tumour initiators, the most important of which are 
benzo[a]pyrene, promoters such as phenol derivatives, complete carcinogens and 
cocarcinogens. Benzo[a]pyrene which occur in amounts of 20 to 40 ng per cigarette 
forms adducts preferentially in the mutation hotspot of p53 gene (Denissenko et al., 
1996). These specific G:C to T:A transversion mutations  contribute 38% of the p53 
mutations in lung carcinoma and are not as abundant in other cancer types (Harris and 
Hollistein, 1993). Smoking increases the risk of all lung cancer types, especially small 
cell and squamous cell carcinoma (Morabia and Wynder, 1992). 
 
1.4.3.2. Asbestos 
Asbestos is a mineral made up of tiny fibres. When it is disturbed, it forms a dust. The 
fibres can be inhaled into the lungs. The most frequent occupational cause of cancer is 
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past exposure to asbestos (Oksa et al. 1997, Steenland et al. 1996). Furthermore, 
interaction between smoking and asbestos has produced a very high risk for lung cancer 
in those with both heavy smoke and asbestos exposures, estimated to be 50 times greater 
than that of the non-smoking, non-asbestos population (Steenland et al. 1996). Asbestos 
can cause chromosome loss and deletion which can lead to accumulation of proto-
oncogenes or inactivation of tumour suppressor genes (Barrett et al. 1989). In lung 
carcinoma, frequency of p53 protein accumulation has been associated with clinical and 
histological asbestos exposure as well as with heavy tobacco smoking (Nuorva et al. 
1994). 
 
1.4.3.3. Genetic alterations 
Lung cancer at molecular level is not well defined and it is believed that multiple genetic 
and molecular changes characterize lung cancer development (Johnson and Kelley, 
1993). Though no gene directly related to lung cancer has been identified, tumour 
oncogenes, suppressor genes, and apoptotic genes are involved in the initiation of lung 
cancer. 
 
1.4.3.3.1. Oncogenes 
1.4.3.3.1.1. Ras 
The Ras gene family mutations are found in approximately 20-30% of lung 
adenocarcinoma and 15-20% of all non-small cell lung carcinoma but very rarely in small 
cell lung carcinoma with K-ras mutations accounting for approximately 90% of Ras 
mutations in lung adenocarcinoma (Richardson and Johnson, 1993).  K-ras and p21 
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proteins form a complex that lead to growth arrest, not proliferation (Kammouni et al., 
2002). The p21-Ras protein is able to bind to quanosine triphosphate (GTP) and has 
intrinsic GTPase activity, which hydrolyzes bound GTP to quanosine diphosphate (GDP). 
When bound to GTP, Ras protein is in its active configuration, which allows the 
transduction of a growth signal to the cell nucleus. When GTP is hydrolyzed, the 
molecule assumes its inactive configuration and the signal transduction falls silent. When 
a Ras gene is mutated, p21-Ras loose its capability to hydrolyze GTP and the molecule 
can no longer switch back to inactive configuration and this result in a continuous and 
inappropriate growth signal to the cell nucleus (Sekido et al., 1998).  
Some studies showed that K-ras mutations are found in only 5-7% of lung tumours from 
non-smoking lung cancer patients. These results suggest that K-ras mutations were 
induced primarily by tobacco-smoke carcinogens. It has been suggested that such 
mutations occur in carcinogen-exposed cells during the mis-replication of a bulky DNA 
adducts formed between a carcinogen and guanine bases in the gene sequence. About 
70% of K-ras mutations are G-T transversions with the substitution of the normal glycine 
with either cystein or valine and this mutations represent the type of DNA damage 
expected from bulky DNA adducts caused by polycyclic hydrocarbons and nitrosamines 
found in tobacco smoke (Slebos et al., 1991). 
 
1.4.3.3.1.2. c-Myc 
 The c-myc gene has emerged as a central oncogenic switch in many human and animal 
cancers. The Myc oncogene family encodes group of nuclear phosphoproteins that play a 
role in cell growth and in the development of human tumours. c-Myc belongs to a family 
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of myc genes that includes B-myc, L-myc, and N-myc, however only c-myc, L-myc and 
N-myc have neoplastic potential. c-Myc affect cell cycle regulation, apoptosis, and 
metabolism positively, whereas it affects cellular differentiation and cell adhesion 
negatively. With deregulated c-myc in tumours, these coordinated activities presumably 
contribute to the neoplastic phenotypes. c-Myc appears to induce apoptosis by a wild type 
p53 dependent pathway. c-Myc might also be related to an activated Fas death pathway 
but using FADD knockout cells, other studies suggest that c-myc induced apoptosis is 
independent of Fas death pathway (Johnson et al., 1996). 
c-Myc has been reported to be more frequently activated in small cell lung carcinoma and 
non-small cell lung carcinoma. Gene amplification of myc family genes has been 
observed in 18% small cell lung carcinoma tumours and 31 % of small cell lung 
carcinoma cell lines. In non-small cell lung carcinoma amplification has been observed in 
8% tumours and 20% cell lines (Johnson et al., 1996). Myc amplification appears to 
occur more frequently in cell lines most derived from metastatic lesions than in primary 
tumours (Richardson and Johnson, 1993).  
 
1.4.3.3.1.3. EGFR 
EGFR belongs to broad family of receptor tyrosine kinases. These receptors have a 
common structure comprising an extracellular ligand binding domain, a transmembrane 
domain and an intracellular domain with tyrosine kinase activity for signal activation. 
Binding of a ligand such as epidermal growth factor causes EGFR to dimerize with itself 
or another member of EGFR family of receptors, leads to receptor linked tyrosine 
activation and results in a signalling cascade (Mendelsohn and Baselga, 2000). EGRF is 
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expressed on the exterior of normal and neoplastic cells. EGFR is frequently altered in 
epithelial tumours and its expression has been associated with advanced stage, poor 
prognosis, and/or resistance to therapy (Brabender et al., 2001; Gupta and raina, 2010). 
EGFR over-expression has been associated with the pathogenesis, proliferation, invasion 
and metastasis of various solid tumours including NSCLC. EGFR is over-expressed in 
approximately 40% to 80% of documented cases of NSCLC and approximately 88% of 
intractable cases of NSCLC. Tumour over-expressing EGFR have a poor response to 
both chemotherapy and radiation therapy.  
 
1.4.3.3.2. Tumour suppressor genes 
Tumour suppressor genes suppress tumour formation by inhibiting apoptosis with their 
protein product. When mutated the mutant allele behave as recessive, that is, as long as 
the cell contain one normal allele, tumour suppression continues. There are a number of 
known tumour suppressor genes but p53 and Rb genes are the well studied. 
 
1.4.3.3.2.1. P53 
Mutation within the tumour suppressor p53 gene is one of the most common genetic 
alterations present in lung cancer. About 70% of small cell lung carcinoma and 50% of 
non-small cell lung carcinoma have mutations in one allele of p53 often accompanied 
with loss of the wild type allele (Brambilla, et al., 2003). Concerning non-small cell lung 
carcinoma, p53 mutations are more frequently found in squamous cell carcinomas than in 
adernocarcinomas and large cell carcinomas (Tammemagi, et al., 1999). Notably, the p53 
mutational spectra of lung cancer show an excess of G:C to T:C transversion (Hainaut 
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and Pfeifer, 2001). Smoking has been shown to be associated with mutations in the p53 
tumour suppressor genes, the most common genetic alterations detected in human 
cancers. Such mutations have been associated with a history of heavy tobacco use, but 
they have also been detected in non-smokers with lung cancer (Beckett, 1993).  
 
1.4.3.3.2.2. Retinoblastoma (Rb) protein 
Rb mutations together with loss of wild type allele have been demonstrated in lung 
cancer (Harbour et al., 1988; Horowitz et al., 1990). Rb protein is abnormal in over 90% 
of small cell lung carcinomas and 15-30% non-small cell lung carcinomas. RB mutations 
in lung cancer include transaction by deletions, nonsense mutations or splicing 
abnormalities (Reissmann et al., 1993). 
Other evidence linking Rb with lung cancer development is suggested by the observation 
that germline carriers of an Rb mutation who were relatives of retinoblastoma patients 
were about 15 times more likely to develop lung cancer than the general population 
(Sanders et al., 1989).  The re-introduction of the wild type Rb gene suppressed the 
growth of SCLC cells (Ookawa et al., 1993). 
 
1.4.3.3.2.3. Tumour suppressor genes at chromosome region 3p 
A cytogenetic deletion in chromosome 3 in lung cancer was first reported by Whang-
Peng et al. The study comprised of 12 cell lines cultured from human small-cell lung 
cancer tissue and 2-day tumour culture specimens from three patients. Acquired 
chromosomal abnormality (deletion at 3p) has been found in at least one chromosome 3 
in 100 percent of the specimens (Whang-Peng et al., 1982).  
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At least three distinct 3p regions have been allelotypically identified suggesting that there 
are probably over three tumour suppressor genes located on 3p (Hibi et al., 1992). One of 
the examples of tumour suppressor genes found at chromosome 3 is FHIT. FHIT is a 
candidate tumour suppressor gene on the basis of frequent loss of heterozygosity (LOH) 
in lung cancer and homozygous deletion in several lung cancer cell lines with most of the 
homozygously deletions found in NSCLC (Yanakisawa et al., 1996). Frequent LOH of 
the FHIT gene was observed in lung cancer from 80% of smokers and 22% non-smokers, 
suggesting that FHIT may be a molecular target of tobacco smoke carcinogens (Sozzi et 
al., 1997). 
 
1.4.3.3.3. Apoptosis genes 
1.4.3.3.3.1. Fas 
Kawasaki and colleagues reported that the expression of Fas in lung cancer cell lines 
varied and that the difference was independent of the cell type. However in general, Fas 
expression in lung cancer is down-regulated and also in some case non-functional. A 
functional Fas-FasL co-expression was found in most lung cancer cell lines. It is not clear 
why these cells expressing both functional Fas and FasL don’t trigger cell death by 
apoptosis, but it is suspected that, since these cells express Fas in low levels, they may 
escape from binding to FasL and therefore the subsequent cell death (Kawasaki et al., 
2000). 
1.4.3.3.3.2. BCL-2 
Bcl-2 protects cells from apoptosis and thus may probably play a role in determining the 
response to chemotherapy through repression of apoptosis in cancer cells because most 
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chemotherapy drugs are designated to induce apoptosis (Ohmori et al., 1993). Studies 
have shown that the frequency of Bcl-2 protein expression is much higher in small cell 
lung carcinoma than in non-small cell lung carcinoma (Jiang et al., 1995). And this is 
contrary to previous studies that small cell lung carcinoma are usually much more 
sensitive to chemotherapy, which usually occurs by apoptosis than non-small cell lung 
carcinoma (Kaiser et al., 1996). Similarly, a better survival of Bcl-2 positive cell lung 
cancer cases was observed in NSCLC and in addition, a longer survival was observed in 
patients whose SCLC tumours express Bcl-2 (Hagashiyama et al., 1997). Thus the role of 
Bcl-2 in lung cancer seems to be complex and not well understood and that the 
suggestion that Bcl-2 may be converted to Bax-like death affectors caspase family of 
cysteine protease may be relevant. 
 
1.4.4. Lung cancer and apoptosis 
Apoptosis can be viewed as a form of programmed cell death that performs a vital role in 
sculpting tissues, organs and organisms. Defects in the regulation of cell death contribute 
to a number of human diseases, e.g. excessive down regulation of this process has been 
linked to cancer and viral infections, while excessive up-regulation causes autoimmune 
disorders and neurodegerative diseases such as Alzheimer’s disease and ischaemic injury 
(Iwahashi et al, 1997)  
It is well known that ectopic expression of tumour suppressor p53 augments apoptotic 
activity in human NSCLC cells incubated with chemotherapeutic agents (Gottliem and 
Oren, 1996). It has been previously reported that human NSCLC cells that have mutated 
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p53 showed significantly poorer response to intensive chemotherapy and able to induce 
drug resistance by interfering with the normal apoptotic pathway (Lai et al., 2000; Israels 
and Israels, 1999). 
Tumour necrosis factors (TNFs) have emerged as one of the main host-derived mediators 
that, either alone or in combination, appear to mediate both antiproliferation and 
tumourigenic effects in malignant tumours. The TNF family is comprised of two 
cytokines, TNF-α (cachectin) and TNF-β (lymphotoxin-α), which are secreted by a wide 
variety of cells. TNFs bind with nearly identical affinities to distinct tumour necrosis 
factor receptors (TNFRs), TNFR-I and TNFR-II. The two cytokines have been reported 
as vital mediators of TNF-α in triggering apoptosis. The expression of TNFR-II can 
strongly induce TNF-  mediated cytotoxicity through TNFR-I in lung cancer cells. 
Although normal lung cancer cells express TNFR-I and -II, loss or downregulation of 
TNFRs occurs during the progression of lung cancers (Li-Feng et al., 2004). It had also 
been reported that retinoic acid modulate the expression of TNFR-I and –II in lung cancer 
cells and sensitise cells to TNF-induced apoptosis (Manna and Aggamal, 2000). These 
findings provide strong evidence that aberrant regulation of apoptosis can be linked to the 
development of lung cancer. 
1.5. Lipoic Acid Synthetase 
Lipoic acid synthetase (LIAS) is a 1.73 kb gene located at chromosome 4p14. Alternative 
splicing occurs at this locus omitting residues 1030-1137 corresponding to exon 10 of the 
full length gene, and two transcript variants encoding distinct isoforms have been 
identified. Variant two lacks exon 10 resulting in a shorter protein (isoform 2) that has a 
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distinct C-terminus, compared to isoform 1 which consist of 11 exons (Mantovani et al., 
2003). The protein encoded by LIAS gene belongs to the biotin and lipoic acid 
synthetases family and localizes in the mitochondrion. 
Though the function of lipoic acid synthetase is not yet well documented, some studies 
have attempted to characterise its function by looking at the biological pathways at which 
LIAS gene product plays a crucial role, one of which being biosynthesis of alpha-lipoic 
acid. Alpha-Lipoic acid is a naturally-occurring enzyme co-factor found in a number of 
multi-enzyme complexes regulating oxidative metabolism. Alpha lipoic acid is also a 
natural antioxidant that is often included in therapeutic drugs for treatment of diseases in 
which pro- and antioxidant balance is disrupted (diabetes, neurodegenerative diseases, 
Acquired Immune Deficiency Syndrome (AIDS)). Research has shown that in diabetic 
retinopathy, oxidative stress increase in the retina and retinal capillary cells undergo 
accelerated apoptosis. Alpha lipoic acid has shown to be very beneficial in the prevention 
of diabetic retinopathy by inhibiting the parameters of oxidative stress generated by high 
glucose concentrations (West, 2000). 
Alpha lipoic acid has recently been the subject of research in HIV. NF-κB binds to HIV 
proviral gene material in the nucleus of HIV infected cells and activates HIV replication. 
Viral replication in turn, increases cellular levels of cytokines such as TNFα that promote 
production of free radicals and activation of NF-κB, initiating a viscous cycle of viral 
replication and free radical production (Pande and Ramos, 2003). Alpha lipoic acid 
appears to directly affect this cycle by completely blocking the activation of NF-κB (Kim 
et al., 2007). 
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Lipoic acid is a crucial cofactor in the pyruvate dehydrogenase (PDH) and alpha -
ketoglutarate dehydrogenase (KGDH) multienzyme complexes responsible for the 
production of acetyl-CoA in metabolic pathways (Busby et al., 1999; Yasuno and Wada, 
2002). 
 
1.5.1. LIAS and apoptosis 
The function of LIAS in apoptosis is not yet well defined but some attempts have been 
made to define its function in apoptosis. It has been reported that alpha-lipoic acid has 
differential effects on the growth and viability of normal versus transformed cell lines. 
Alpha-lipoic acid induced apoptosis in human FaDu and Jurkat tumour cell lines and the 
mechanism of apoptosis was found to be independent of Fas-mediated signalling, as 
alpha-lipoic acid-treated Jurkat cell mutants deficient in Fas or FADD retained sensitivity 
to apoptosis. The differential selectivity of the pro-apoptotic effects of alpha-lipoic acid 
for transformed cells supports its potential use in the treatment of neoplastic disorders 
(Van de Mark et. al., 2003).  
1.6. Ribosomal Protein L9 
The eukaryotic ribosome is a complex structure with two subunits, large (60S) and small 
(40S) composed of four RNA molecules and as many as 80 different proteins. The human 
ribosomal protein L9 gene (RPL9) is approximately 5.5 kb in length and contains 8 
exons. It is located on chromosome 4p14. The message for RPL9 is 712 nucleotides in 
length. This gene encodes a ribosomal protein that is a component of the 60S subunit. 
The protein localises in the cytoplasm. As is typical for genes encoding ribosomal 
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proteins, there are multiple processed pseudogenes of these genes dispersed through the 
genome (Mazuruk et al., 1996).  
1.6.1. RPL9 and apoptosis  
RPL9 has been highly conserved through evolution. The amino acid sequence of mouse 
and human RPL9 is 98% identical. For decades mouse have been used as human models 
in research hence the use of 6132A PRO mouse cells to investigate the effect of L9 to 
cancer. cDNA sequence of L9 from UV induced 6132A PRO tumour cells, differ from 
the normal sequence at one nucleotide: A instead of T. This mutation encodes histidine 
instead of leucine at position 47. Antigenic activity was found at high level in ribosomes 
isolated from 6132A-PRO cells. Reintroduction of the lost wild type L9 allele into 
6132A-PRO variant suppressed the growth of tumour cells in vivo (Paul et.al. 1995). The 
highest expression levels of eukaryotic ribosomal protein genes have been observed in 
cells undergoing growth and development and that the level of expression declines as the 
tissue reaches developmental maturity (Williams and Sussex, 1995). 
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Main Objective 
 
The purpose of this study was to establish the expression of the RPL9 (ribosomal 
protein gene) and LIAS (lipoic acid synthetase) genes in human lung cancer and to 
characterize their role in apoptosis and lung cancer and also to determine whether the 
expression levels of this two genes varies between the normal and the diseased state 
of the tissue. 
 
Rationale 
Since there is strong evidence that suggest that aberrant regulation of apoptosis can be 
linked to the development of cancer, the generation of well characterized mutants that are 
resistant to apoptosis can potentially provide useful tools to study the action and 
efficiency on known and novel drugs directed against cancer. The identification of such 
genes would provide novel targets for drug development to treat diseases such as cancer. 
Both LIAS and RPL9 genes were found mutated in CHO cell lines that gained resistance 
to apoptosis due to promoter-trap mutagenesis. The work was done at the University of 
the Western Cape, in Prof D.J.G Rees laboratory (unpublished). As already briefly 
indicated above the link between apoptosis and these two genes, it is imperative to further 
study the direct relationship between them and apoptosis in human cancers and in this 
case, human lung cancer.  
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2. Materials and Methods 
2.1. Sample collection 
Ethics clearance was obtained from Human Ethics Committee, University of the 
Witwatersrand, clearance number (M050308). The normal and cancerous lung tissue 
sections were obtained from National Health Laboratory Service, department of 
Pathology. Cancer cases provided were Adenorcarcinoma, Large cell carcinoma, 
Squamous cell carcinoma, Small cell carcinoma. Normal lung cell line (Fibroblast MRC-
5) and lung adenorcacinoma (A549) cell lines (Highveld Biologicals, South Africa) were 
used for RNA extraction. 
2.2. Preparation of Competent Cells 
Normally Escherichia coli cells do not possess the ability to take up DNA from the 
environment. However, if their cell walls are altered, these bacterial cells become more 
likely to incorporate foreign DNA and thus these cells are said to be “competent”. These 
cells can be made competent by chemical or physical treatment. Chemical treatment 
includes the calcium chloride method while physical treatment includes electoporation 
whereby the bacterial cell is shocked with 2500 V. In preparation of competent cells, 
cells in the log phase are used as they are undergoing rapid growth and become 
competent more easily than cells in any other growth stage.  
Chemical treatment was used in order to make MC1061 Escherichia coli cells competent.   
1. MC1061 cells were plated on Luria Bertani (LB) agar plates containing 10 mM 
Magenesium Chloride (MgCl2). The plates were incubated at 37 °C overnight. 
2. A single colony was added to 20 ml Tryptone Yeast Extract MgCl2 (TYM) Broth in a 
500 ml conical flask and grown at 37 °C overnight, shaking constantly at 300 rpm. 
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3. Following an overnight incuation, 1 ml of cells in the TYM Broth were added to 100 
ml fresh TYM Broth in a 2 L conical flask. The cells were grown for a further 2-3 
hours or until optical density at 550 nm lies between 0.4 and 0.6 at 37 °C hours with 
constant shaking at 300 rpm.  
4.  Thereafter, 400 ml of fresh TYM broth was added to the 2 L conical flask and cells 
allowed to grow for a further 2-3 hours or until optical density at 550 nm lies between 
0.4 and 0.6 at 37 °C with constantly shaking at 300 rpm 
5. Bacterial cells were rapidly cooled in ice water, shaking constantly after which they 
were centrifuged in two 125 ml propylene tubes at 3000 rpm for 10 minutes at 4 °C. 
6. The supernatant was discarded and the pellet resuspended in 125 ml Tfb1. This 
solution was allowed to incubate for 30 minutes on ice after which the bacterial cells 
were centrifuged at 3000 rpm for 10 minutes at 4 °C.  
7. The bacterial cells were gently resuspended in 80 ml Tfb2. 300 µl of the cells were 
aliquoted into 0.5 ml eppendorf tubes. The cells were then frozen on dry ice and 
stored at -70 °C for further use.  
 
2.3. In Situ Hybridization 
In situ hybridization is a technique used to view the location of nucleic acids in situ, i.e. 
in their native location in the cell or nucleus. For viewing the location of RNA in the cell, 
the tissue is gently fixed so as not to disrupt the double stranded DNA. Tissues are then 
hybridized to a chemically or radioactively labelled RNA or DNA probe that is 
complimentary (or anti-sense) to the desired mRNA of interest. The chemical or 
radioactive probe can then be detected in the tissue by antibodies to the chemical label or 
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by autoradiography. When using the chemically labelled probe the antibody may be 
fluorescently labelled (fluorescence) or can have an enzyme (colorimetric) associated 
with it that when exposed to substrate there is an emission of light at a specific 
wavelength or generates a coloured precipitate respectively so that localization in cells is 
easy. In this study both fluorescence and colorimetric methods were used.   
 
2.3.1. RNA isolation 
Total RNA was extracted using the Trizol
TM
LS reagent method. The method can be 
divided into four stages, the disruption, homogenisation, phase separation and RNA 
precipitation stages. During the disruption stage the cell wall, plasma membrane of the 
cell and organelles found in the cell are disrupted allowing for the release of all the RNA 
contained in the sample. At homogenisation the viscosity of the cell lysates produced 
during disruption is reduced and the shearing of high molecular weight genomic DNA 
and other high molecular weight cellular components occurs using the TRIzol
TM
 LS 
Reagent. RNA is separated from the rest of the lysate using chloroform while RNA is 
isolated by RNA precipitation using isopropyl propanol  
1. RNA was extracted from normal lung fibroblast cell line MRC5. The cells were 
cultured in a 25 cm
3
 tissue culture plate in 10 % Foetal Bovine Serum (FBS)-
Dulbecco’s Modified Eagled Medium (DMEM) (Highveld Biologicals, 
California) until they were confluent. 
2. The cells were grown in a monolayer that is attached on the culture plate and they 
were washed with PBS before RNA was extracted.  
3. The cells were then homogenised by adding 2 ml TrizolTMLS reagent (Invitrogen 
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Corporation, Life Technologie, Carlsbad, CA, USA) per 25 cm
3
 of culture plate 
with vigorous shaking for 2 hours.  
4. Cells were completely homogenised by passing the lysate through the pippet a 
several times. 
5. The homogenate was split into two 1 ml and each 1ml was transferred to a 2 ml 
eppendorf tube. 1 ml of chloroform (Merck Chemicals (Pty) Ltd, Gauteng, South 
Africa) was added to each tube and vigorously vortexed for 30 seconds  followed 
by incubation at RT for 10 minutes 
6. The homogenate was then centrifuged at 4º C for 1 hour at 12000 rpm. 
7. After centrifugation the combined top aqueous layer was transferred to a clean 2 
ml eppendorf  tube to which 1 ml isopropyl alcohol (Merck Chemicals (Pty) Ltd, 
Gauteng, South Africa) was added and mixed thoroughly by inverting the tube a 
several times and then incubated at 4 ºC for 30 minutes so as to precipitate the 
RNA 
8. RNA was pelleted by spinning at 12000 rpm for 30 minutes at 4º C and 
immediately supernatant was discarded. 
9. The RNA pellet was then washed with 1 ml 70 % ethanol by centrifuging the 
mixture at 12000 rpm for 5 minutes at 4 ˚C. 
10. Supernatant was immediately discarded, pellet dried and re-suspended in 100 µl 
DEPC water and stored at -70 ºC 
11. The quality of the RNA extracted was determined by formaldehyde agarose gel 
electrophoresis (Section 2.3.2.) and quantified spectrophotometrically 
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Quantification of RNA 
[RNA] in μg/μl   =   40X dilution factor XOD 
                                             1000 
 
          
2.3.2. Formaldehyde agarose gel electrophoresis 
Quality of extracted RNA was analysed on 1 % (w/v) agarose gel. The gel was prepared 
by dissolving 1g agarose in 10 ml of 10 X 3-[N-morpholino] propane sulfonic acid 
(MOPS) (Fluka Chemie GmbH, Sigma-Aldrich Chemie, GmbH, Steinheim, Switzerland) 
and 84.6 ml sterile DEPC treated water. The gel was allowed to cool to 50 ºC prior to 
addition of 5.4 ml 37 % (v/v) formaldehyde (Riedel-de-Haën, Sigma Aldrich 
Laborchemikalien GmbH, Seelze) and 4 µl of 100 µg/ml ethidium bromide (Merck 
KGoA, Darmstadt, Germany). The gel was poured into a casting tray and allowed to set 
at room temperature. 10 µl RNA sample was mixed with freshly prepared formaldehyde 
gel loading buffer and the mixture was then heated at 65 ºC for 5 minutes to denature 
RNA and cooled on ice for 10 minutes before loading on the gel. Once the gel was 
completely set, the comb was carefully removed and the gel placed on electrophoresis 
tank. 1 XMOPS was added to the tank until the gel was completely submerged. RNA 
mixture was loaded into the wells and electrophoresed at 50V for 1 hour or until the 
loading dye reached three-quarters of the gel. After the run the gel was visualised and 
photographed using Universal Hood II UV transluminator (Bio-Rad Laboratories, 
Hercules, CA, Italy) and the QuantityOne-D-Analysis Software (Bio-Rad Laboratories, 
Hercules, CA, USA). 
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2.3.3. Reverse transcription- Polymerase Chain Reaction 
Reverse transcription polymerase chain reaction is the most sensitive method for the 
detection of the low abundant mRNA often obtained from cell lines or limited tissue 
samples. mRNA was reverse transcribed into cDNA using ImProm-II Reverse 
Transcription system (Promega Corporation, Madison, WI, USA) and manufacturer’s 
instructions were followed. The oligo-p(dT)15 was used. Oligo-p(dT)15 primer binds to 
the 3’-end poly (A) tail of mRNA and together with reverse transcriptase, mRNA is 
reverse transcribed into cDNA. Reaction volumes and concentrations are shown in table 
2.1. 
Table 2.1: cDNA synthesis cocktail 
Reagents Volumes per sample Final concentration 
5 X Reaction buffer 5 µl 1 X 
25 mM MgCl2 3 µl 3 mM 
10 mM deoxyribonucleotide mix 2.5 µl 1 mM 
Oligo-p(dT)15 1 µl  
RNAse inhibitor 0.5 µl  
AMV Reverse Transcriptase 1 µl  
Sterile distilled water X µl  
RNA sample X µl  
Total volume 25 µl - 
X depends on the RNA concentration 
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Reverse transcriptase was added last to avoid degradation. The mixture was then briefly 
vortexed and centrifuged to collect the mixture at the bottom of the tube. The reaction 
was carried out under the following conditions. 
25 ºC for 10 minutes 
42 ºC for 60 minutes 
75 ºC for 15 minutes 
4 ºC for 10 minutes 
cDNA was then stored at -20 ºC until used for Polymerase Chain Reaction (PCR). 
 
2.3.4. Primers design and synthesis 
Primers for RPL9 and LIAS were designed and synthesised at Inqaba Biotech (RSA). 
The primer sequences were confirmed using the NCBI BLAST search engene. Primers 
sequences, product sizes and annealing temperatures are shown in table. 
 
Table 2.2: Primer sequences for RPL9 and LIAS  
 
Gene 
 
Primers Sequence 
PCR 
amplicon 
size 
Annealing 
Temperature  
(Tm) 
LIAS  Forward taagactgcaagaaatcctcctcc 
Reverse cacaaggatttttggattcctttcc 
190 bp 57 ºC 
RPL9 Forward ctccgggttgacaaatggtgg 
Reverse cccattctcctggataacaacg 
165 bp 61 ºC 
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2.3.5. Polymerase Chain Reaction 
Polymerase chain reaction (PCR) is a three step technique that allow for amplification of 
minute DNA quantity into a significant quantity of the fragment of interest through 
repetitive cycle of DNA synthesis. The three PCR steps are denaturation in which case 
the temperature is taken up to as high as 94 ºC. At this temperature the two DNA strands 
separate (denature). The second step is annealing of primers to the templates (denatured 
DNA strands). The temperature is taken down specific for the set of primers used which 
is normally 5 ºC less than the melting temperature (Tm). The last step is polymerisation 
(elongation) of the annealed primer. DNA polymerase is used to synthesise a double 
stranded DNA by complementary base pairing with the DNA template. It is essential to 
use a thermo stable DNA polymerase that can withstand the harsh denaturation 
temperature and for this reason Taq polymerase is often used which elongate or 
polymerise at 72 ºC. After elongation the cycle starts again and production is exponential. 
The cDNA obtained through reverse transcription was used as a template using sequence 
specific primers for LIAS and RPL9. Master Mix from (Promega Corporation, Madison, 
WI, USA) was used and instructor’s manual was followed. Reaction components and 
concentration are shown in table 2.3.     
Table 2.3: Cocktail for Polymerase Chain Reaction 
Reagent Volume Final concentration 
Master Mix 12.5 µl 1 X 
Forward Primer (10 ρmoles) 1 µl 0.4 ρmoles/ µl 
Reverse Primer (10 ρmoles) 1 µl 0.4 ρmoles/ µl 
25 mM MgCl2 2.0 µl 2 mM 
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Sterile nuclease free water y  
Template DNA x 1 µg 
Total volume 25 µl  
x and y – variable depending on cDNA concentration 
The reaction was carried out under the following conditions depending on the gene of 
interest and primer set used. 
95 ºC for 2 min 
94 ºC for 30 sec 
Tm -5 ºC for 30 sec 
72 ºC for 1 min 
72 ºC for 10 min 
4°C for ∞ 
 
2.3.6. Agarose gel electrophoresis for DNA 
Agarose gel electrophoresis is a technique used for separation of nucleic acids according 
to size, charge and shape. Using a stain like ethidium bromide which intercalates between 
the bases of DNA and illuminate the gel under UV light, DNA fragments can be 
visualised. 0.8 % agarose gel was prepared by dissolving 0.8 g agarose in 100ml 1 X 
TBE buffer. Ethidium bromide to a final concentration of 1 µg/ml was added when the 
solution reaches 50 ºC and allowed to set in a gel-casting tray. The DNA samples were 
mixed with 1 X Orange-blue loading dye (Fermentas Life Sciences, Hanover, MD, USA). 
Generuler
TM
 100 base pair DNA ladder was used (Fermentas Life Sciences, Hanover, 
MD, USA). The DNA samples and DNA molecular weight marker were loaded onto the 
35 cycles 
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gel and run at 70 V in 1 X TBE buffer. The gel was allowed to run until the dye reached 
three quarters of the gel after which gel was viewed and image captured using a UV 
transluminator.   
 
2.3.7. Cloning 
Cloning is an umbrella term traditionally used to describe different processes for 
duplicating biological material. The different types of cloning are recombinant DNA 
technology or DNA cloning, reproductive cloning, and therapeutic cloning. Cloning 
technology used in this study was DNA cloning which is defined as a transfer of DNA 
fragment of interest from one organism to a self-replicating genetic element such as a 
bacterial plasmid. The DNA of interest can then be propagated in a foreign host cell. 
Cloning makes it easy to sequence DNA fragment of interest because cloned fragments 
can be prepared to obtain required DNA concentration for sequencing  and other 
applications such as probe synthesis. 
 
2.3.7.1 Ligation 
PGEM-T-Easy vector allows for cloning of PCR products without purifying them. 
LigaFast
TM
 Rapid Ligation System (Promega Corporation, Madison, WI, USA) was used 
to clone PCR products into pGEM-T-Easy vector for both sequencing and probe 
synthesis. Ligation mixture consisting of 3 ng PCR product and 10 ng pGEM-T-Easy 
vector was prepared and ligation was carried out by T4 DNA ligase. Background control 
(no insert) was also setup as well as a positive control supplied with the kit. The 
components were mixed and briefly centrifuged to collect everything at the bottom of the 
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tube. The ligation mixture was incubated at room temperature for a minimum of one 
hour. After the hour the ligation mixture was transformed into MC1061 E. coli cloning 
strain competent cells. 
 
Table 2.4: Ligation 
Reagents Experimental 
Reaction 
Negative Control 
Reaction 
Positive Control 
Reaction 
2 X ligation buffer 5 µl 5 µl 5 µl 
PCR product 3 ng - 3 ng 
pGEM-T-Easy 10 ng 10 ng 10 ng 
T4 ligase 1 µl 1 µl 1 µl 
SdH2O Adjust to 10 µl Adjust to 10 µl Adjust to 10 µl 
Total volume 10 µl 10 µl 10 µl 
 
 
2.3.7.2. Transformation  
E. coli competent cells were thawed on ice before use. 100 µl of these cells were added to 
ligation mixture set above. This was incubated for 30 minutes on ice. Immediately 
followed by incubation at 37 ºC for 5 minutes to heat shock the cells and then followed 
by incubation for 2 minutes on ice. 900 µl of Luria broth (LB) lacking ampicillin was 
added onto the mixture and incubated for one hour at 37 ºC to allow for the growth of 
cells. After the hour, transformation mix (100 µl) was plated on pre-warmed Luria agar 
plates containing ampicillin. The plates were then incubated at 37 ºC overnight. 
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Note: negative control was cells with no plasmid DNA transformed into them while 
positive control was supplied with the kit i.e. a DNA fragment that was assured to ligate 
to pGEM-T-Easy cloning vector. And the background control was cells transformed with 
pGEM-T-Easy vector with no insert to check if the vector was ligating to itself.  
 
2.3.8. Colony Polymerase Chain Reaction 
Colony PCR is a technique that uses PCR technology to identify and select cell colonies 
that have the correct plasmid insert. Instead of using purified DNA, colony mixed with 
water is used as a template for PCR reaction. 
Aliquots of 10 µl of sterile distilled water were added into a set of 0.2 ml eppendorf tubes 
corresponding to a number of colonies to be screened. Each colony was mixed with 
sterile distilled water in its own eppendorf. 1 µl of each colony mix was used as a 
template for PCR reaction as tabulated on table 2.3. Sequence specific primers were used 
to find the insert of interest. At the end of PCR the results were analysed on 0.8 % 
agarose gel electrophoresis (Section 2.3.6). Colonies that showed the presence of the 
DNA fragment of the correct size was taken through to plasmid DNA extraction. The 
remainder of the 10 µl of colony mix was used to inoculate an overnight culture for 
plasmid DNA extraction.   
 
2.3.9. Plasmid DNA extraction 
In order to get a high quality DNA for subsequent experiment such as sequencing and 
probe synthesis, plasmid DNA was extracted using Promega WizardPlus® Miniprep 
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DNA Purification System (Promega Madison, WI, USA). Manufacturer’s instructions 
were followed and the full protocol is outlined below. 
 
Plasmid DNA extraction protocol 
1. An overnight culture was prepared by inoculating 6 ml luria broth with ampicillin 
with a colony containing plasmid of interest overnight. 
2. 6 ml of an overnight culture was centrifuged at 12 000 rpm for 8 minutes at RT. 
3. Supernatant was carefully discarded and pellet resuspended in 250 µl Cell 
Resuspension Solution. 
4. 250 µl Cell Lysis Solution was added to the cell suspension and tube inverted 4-5 
times to mix 
5. 10 µl Alkaline Protease Solution was added. The tube was inverted 4-5 times to 
mix followed by incubation at RT for 5 minutes. 
6. 350 µl Neutralizing Solution was added and the tube inverted 4-5 times to mix. 
7. The sample was centrifuged at 12 000 rpm for 10 minutes at RT. 
8. Spin column was inserted into collection tube. 
9. Cleared lysate was poured off into spin column assembly followed by 
centrifugation at 12 000 rpm for 1 minute at RT. 
10. The flow through was discarded and spin column reinserted into the collection 
tube. 
11. 750 µl Wash Solution (Ethanol added) was added followed by centrifugation at 
12 000 rpm for 1 minute at RT. 
12. The flow through was discarded and spin column reinserted into collection tube. 
   49 
 
13. Step 11 was repeated with 250 µl Wash Solution and centrifuged for 2 minutes at 
RT 
14. Spin column was inserted into a clean sterile 1.5 ml eppendorf tube. 
15. Plasmid DNA was eluted into the eppendorf tube by adding 50 µl nuclease-free 
water to the spin column followed by centrifugation at top speed for 1 minute at 
RT. 
16. Spin column was discarded and plasmid DNA stored at -20 ºC. 
17. To determine if plasmid DNA was isolated the results were analysed agarose gel 
electrophoresis (Section 2.3.6) 
 
 
2.3.10. Sequencing 
Sequencing was done at Inqaba Biotech (Pretoria, RSA). Sequences were analyzed using 
CHROMAS, version 1.62 (Technelysium (Pty) Ltd, Australia) and BLAST tool from the 
National Centre for Biomedical Information (NICB) at URL: www.ncbi.nlm.nih.gov to 
compare the sequence obtained to a reference sequence Accession number 
 
2.3.11. Linearization of clones 
The first step of probe synthesis is linearization of clones with PstI and ApaI. PstI cuts 
the pGEM-T-Easy clone vector at the Sp6 side of the insert so that the T7 promoter can 
be used for in vitro transcription of the antisense probe. ApaI cuts pGEM-T-Easy vector 
at the T7 side of the insert and this allows for in vitro transcription of the sense probe 
using the Sp6 promoter. Restriction digestion setups are illustrated in table 2.5. 
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Table 2.5: Linearisation of clones 
 PstI digest ApaI digest 
pGEM-T-Easy clone 10 µl 10 µl 
10 X Buffer 2 µl - 
10 X Buffer - 2 µl 
PstI 3 µl - 
ApaI - 3 µl 
SdH2O 15 µl 15 µl 
Total volume 30 µl 30 µl 
 
The reaction digestions were incubated at RT overnight and then the enzymes were 
inactivated by incubating the tubes at 65 ºC for 5 minutes. To check if the clones were 
completely linearised, 5 µl of the reaction was run on 0.8 % agarose gel electrophoresis. 
After verifying that the clones were completely linearised, the rest of the reaction digest 
was run on 0.8 % agarose gel (Section 2.3.6) and purified from the gel as described in 
section 2.3.12 
 
2.3.12. Purification of DNA from Agarose Gel 
Wizard SV gel and PCR clean-up system (Promega Corporation, Madison, WI, USA) 
was used to purify the linearized clones from agarose gel for probe labelling. 
Manufacturer’s instructions were followed and the protocol is outlined below. 
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1. Linearized clone was electrophoresed on 0.8 % agarose gel 
2. DNA band was visualised with a long wavelength UV light and excised 
out with a sharp sterile blade.  
3. Gel slice was transferred to a weighed eppendorf and its mass calculated. 
4. Gel slice was dissolved in 10 µl membrane binding solution for each 10 
mg of the slice. 
5. The gel slice mix was incubated at 65 ºC for 10 minutes or until the gel 
dissolved completely with occasional mixing. 
6. Once dissolved, SV mini column was inserted into collection tube and 
dissolved gel poured into the SV mini column assembly and incubated at 
RT for 1 minute. 
7. This was followed by centrifugation in a microfuge at 10 000 rpm for 1 
minute at RT. The flow through was discarded and the mini column 
reinserted into the collection tube. 
8. 700µl of membrane wash solution (ethanol added) was added to the mini 
column and followed by centrifugation at 10 000 rpm for 1 minute at RT. 
9. Step was repeated with 500 µl membrane wash solution and centrifuged 
for 5 minutes at the same speed. 
10. The SV mini column was carefully removed from the assembly making 
sure that the mini column did not touch the flow through. 
11. SV mini column was then inserted into a sterile 1.5 ml sterile eppendorf. 
12. 50 µl sterile DEPC treated water was added to the centre of the column 
and incubated at RT for 1 minute followed by centrifuged at 10 000 rpm 
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for 1 minute. 
13. SV mini column was discarded and the DNA was quantitated 
spectrophotometrically and stored at -20 ºC for labelling. 
 
2.3.13. Digoxygenin (DIG) Probe Labelling 
Purified, linearized clones with RPL9 and LIAS inserts were used as templates for 
labelling of the sense and antisense cRNA probes. For the generation of the antisense 
probe, 2 µg of the PstI linearized clone was incubated with DIG dUTP and T7 RNA 
polymerase and for the generation of the sense probe, ApaI linearised clone was 
incubated with Sp6 RNA polymerase. The specificity of the labelling reaction was 
determined by generating a DIG labelling control RNA from DNA PSPT 18-Neo/Pvu II 
supplied with the kit. The reaction mixture of the DIG labelling of the sense, antisense 
and control RNA probes was generated by adding the reagents as tabulated in table 2.6. 
The reaction mixtures were PCR incubated at 37 ºC for two hours. After the incubation 
the reaction was stopped with 4 µl 0.2 M EDTA (pH 8.0). These were briefly mixed and 
pulse spun to collect everything at the bottom of the tube. 4.4 µl 4M Lithium chloride 
was added. 150 µl absolute ethanol was added to precipitate the labelled cRNA. This was 
briefly mixed and pulse spun to collect everything at the bottom of the tube. The reaction 
was then incubated at -20 ºC for 2 hours. After the incubation the precipitate was pelleted 
by centrifugation at 4 ºC for 15 minutes at 13 000 rpm. The supernatant was discarded 
and pellet washed with 200 µl cold 70 % ethanol by centrifuging at 13 000 rpm for 15 
minutes at 4 
o
C after which the supernatant was carefully removed with a pipette to avoid 
losing the pellet. The pellet was then dried in a laminar flow for two hours. After two 
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hours the pellet was dissolved in 50 µl sterile DEPC treated water. The pellet was 
allowed to dissolve completely at 4 ºC for 1 hour. The DIG labelled cRNA transcripts 
were stored at -70 ºC in 10 µl aliquots.  
 
Table 2.6: DIG labelling reaction mix 
Reagent Antisense cRNA Sense cRNA Control cRNA 
LIAS (B) (2 µg) 10 µl 10 µl - 
LIAS (V1) (2 µg) 10 µl 10 µl - 
RPL9 (2 µg) 10 µl 10 µl - 
Control DNA PSPT 18-Neo/PvuII - -  
10X NTP labelling mix 2 µl 2 µl - 
10X Transcription buffer 2 µl 2 µl 2 µl 
T7 RNA polymerase 2 µl - - 
Sp6 RNA polymerase - 2 µl - 
DEPC H2O 4 µl 4 µl  
Total volume 20 µl 20 µl  
 
ADJUSTMENTS 
RNAse inhibitor was not added as it requires high concentration of DDT (dithiotretiol) 
fro activity and DDT affects T7 and Sp6 activity.  
DNAse was not used as it may not be RNAse free and also because it might leave too 
little DNA template to label. 
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2.3.14. Estimation of probe concentration 
The concentration of anti-sense and sense probes was estimated by comparing the 
intensity of the spots with that of DIG labelled cRNA supplied with the kit. DIG user’s 
guide (Roche Diagnostics, Germany) was used. Dilutions for labelled anti-sense, sense, 
DIG labelled cRNA to control DNA pSPT-18-Neo and control labelled cRNA supplied 
with kit were made as tabulated in table 2.7. Spot points corresponding to the number of 
probes and the number dilutions were marked lightly with a pencil on nylon membrane 
(Hybond). 1 µl of each dilution was spotted on the marked point on the membrane and 
allowed to air dry for 5 minutes at RT. The probes were fixed on the membrane by 
placing the membrane under UV light for 5 minutes. The membrane was washed with 1 
X washing solution (Roche Diagnostics, Germany) while shaking for 5 minutes. The 
membrane was then incubated with 1 X blocking buffer to cover the membrane with 
shaking for 30 minutes (Roche Diagnostics, Germany). This was followed by incubating 
the membrane with Anti-DIG-Alkaline phosphatase (Roche Diagnostics, Germany) 
diluted in 1:10000 in 1 X blocking buffer for 30 minutes. The membrane was washed 
twice in 1X washing buffer to cover the membrane with shaking for 15 minutes for each 
wash. After washing, the membrane was incubated in 1 X detection buffer (Roche 
Diagnostics, Germany) with shaking for 2 minutes. The membrane was further incubated 
in NBT/BCIP (Roche Diagnostics, Germany) diluted in 1:50 detection buffer enough to 
cover the membrane while shaking. It was then allowed to develop overnight. The 
reaction was terminated in 50 ml TE buffer (pH 8.0) with shaking for 5 minutes. The 
membrane was air dried and probe concentrations estimated from that of the DIG labelled 
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cRNA provided with the kit by comparing the colour intensity of the spots that develop 
on the membrane. 
 
Table 2.7. Dilutions for the estimation of the probe concentration 
Dilution DIG labelled cRNA DIG labelled cRNA to 
the control DNA 
Antisense and Sense 
probes 
Initial Conc. 0.1 µg/µl ~50 ng/µl  
Dilution 1 1:5 
1 µl + 4 µl SdH2O 
 1:10 
1 µl + 9 µl SdH2O 
Dilution 2 1:20 
2 µl + 38 µl sdH2O 
1:5 
2 µl + 38 µl sdH2O 
1:20 
2 µl + 38 µl sdH2O 
Dilution 3 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 
Dilution 4 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 
Dilution 5 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 
Dilution 6 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 
Dilution 7 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 5 µl + 45 µl SdH2O 
  
  
For each dilution, the previous dilution was diluted in water to make the next dilution, i.e. 
dilution 3 = 5 µl dilution 2 plus 45 µl SdH2O.  
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2.3.15. Procedure for In Situ Hybridization 
This procedure can be divided into three major steps, pre-hybridization treatment of 
section, hybridization and post-hybridization. Pre-treatment is the step at which tissue 
sections are de-waxed and treated with various chemicals to reduce the background 
staining. Hybridization is the step at which the DIG labelled RNA bind to mRNA of 
interest in the tissue sections. Post-hybridization at which excess or unbound probe is 
washed off and probe bound to mRNA can be colorimetrically or fluorescently detected 
thus locating the gene at RNA level. 
 
Two controls were used in this study. A negative control which was hybridization with 
the sense probe, thus allowing determining if localization was specific and if localization 
occurred when tissue sections were hybridized with anti-sense probe. The second control 
was the normal tissue section which is used to determine if there is any difference of 
expression in the cancer tissue section this being the main objective of the study.  
 
2.3.15.1. Pre-hybridization treatment of sections 
Prior to pre-treatment of sections, 0.5 % acetic anhydride and 4 % paraformaldehyde 
(PFA) in 100 mM phosphate buffer were freshly prepared and 1 X TBS chilled at 4 °C.   
 
Tissue sections were de-waxed in fresh xylene (Saarchem, Merck Chemical (Pty) Ltd, 
Gauteng, South Africa) for 30 minutes (three changes of 10 minutes each) at RT. Tissue 
sections were then rehydrated in fresh absolute ethanol for 6 minutes which consisted of 
2 changes of 3 minutes each at RT. This was followed by a further rehydration in 90 %, 
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70 %, 50 % ethanol and DEPC treated water for 3 minutes in each. Sections were fixed in 
freshly prepared 4 % PFA for 20 minutes at RT. They were then rinsed three times in 
fresh 1 X Tris Buffer Saline (TBS) consisting of 3 changes of 1 minute each at RT. 
Proteins were denatured in 0.1 M HCl for 10 minutes followed by rinsing 3 times in TBS 
which consisted of 3 changes of 1 minute each at RT. Non-specific binding was limited 
by incubating the section in 0.5 % Acetic Anhydride in 100 mM Tris (pH 8.0) for 10 
minutes at RT. The sections were then rinsed 3 times in TBS (3 changes of 1 minute 
each). Cell membranes were permeabilized with 20 µg/ml Proteinase K (Roche 
Diagnostics, Germany) in 1 X TBS for 20 minutes The sections were rinsed 3 minutes in 
TBS (3 changes of 1 minute each) at RT. Proteinase K activity was terminate by 
incubating the sections in 4 °C TBS for 5 minutes.  The sections were then dehydrated by 
incubating them in DEPC treated water, 50 %, 70 % and 90 % ethanol respectively for 1 
minute in each. The sections were further dehydrated in absolute ethanol for 2 minutes (2 
changes of 1 minute each) after which they were dried in chloroform for 10 minutes in 
fume cupboard. At this point the sections can be kept in a dry and dust free area. 
 
2.3.15.2. Hybridization                                
In section 2.2.14 the minimal amount of both antisense and sense cRNA for LIAS and 
RPL9 probes that could be detected was 10 ρg. The dilutions were worked up to 
determine the concentration of the undiluted probes which was found to be 2 ng/µl.  
 
1 µl of each probe (sense and anti-sense) was added to 900 µl of hybridization buffer. 
This was followed by boiling of the solution for 5 minutes and placed immediately on ice 
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for 2 minutes. Thereafter, 100 µl of the hybridization mix was placed on each slide and 
allowed to hybridize overnight in a humidity chamber at 55 ºC. To limit evaporation of 
hybridization mix, a solution of 5 X SSC (3M NaCl, 0.3 M Na-citrate, pH 7.0) buffer and 
50 % formamide was prepared and poured into the hybridization chamber. 
 
2.3.15.3. Post-Hybridization  
After hybridization, sections were subjected to various concentrations of SSC to wash-off 
excess probe. Firstly the sections were washed in 2 X SSC for 30 minutes at 37 ºC in 
hybridization oven. Sections were further washed in 1 X SSC, 0.5 X SSC and 0.1 X SSC 
for 20 minutes each at 55 ºC. The slides were rinsed in TBS for 3 minutes consisting of 3 
changes of 1 minute each at RT. Non-specific binding was blocked by incubating the 
sections with 100 µl of 1 X blocking solution to each slide in a humid chamber for 2 hrs 
at RT. The protocol here after varies depending on the detection method to be used. 
 
2.3.15.3.1. Colorimetric Detection 
DIG-labelled RNA probes that have hybridized to the target sequence can be detected 
colorimetrically with alkaline phosphatase conjugated to anti-DIG. Incubating the 
sections with a suitable substrate such as NBT/BCIP allow for alkaline phosphatase 
activity which results in the formation of a purple/blue precipitate that can be viewed 
under light microscope.  
 
The sections were incubated with 100 µl anti-DIG IgG conjugated with alkaline 
phosphatase diluted in 1:500 1 X blocking solution per slide in a humid chamber for 1 hr 
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at RT. The slides were rinsed in TBS for 3 minutes (3 changes of 1 minute each) at RT. 
Thereafter the sections were incubated with 100 µl chromogen NBT/BCIP diluted 1:50 in 
1 X detection buffer. 100 µl was added to each slide and left to develop in a dark humid 
chamber overnight at RT. The reaction was stopped by incubating the slides in 1 X TE 
buffer for 5 minutes. The slides were then washed in running tab water for 5 minutes at 
RT. Tissue sections were counterstained with 5 drops of Mayer’s Haematoxylin per slide 
for 5 minutes followed by washing in running tap water for 10 minutes. Thereafter the 
sections were mounted with glycerine jelly and allowed to dry at RT. Tissue sections 
were then viewed and images captured using the Zeiss Microscope Camera and Axio 
software package. 
 
2.3.15.3.2. Fluorescent Detection 
Alternatively, DIG-labelled RNA probes hybridized to the target sequence was detected 
fluorescently with fluorescein isothicyanate (FITC) conjugated to anti-DIG. FITC does 
not require the presence of a suitable substrate in order to emit a colour precipitate. FITC 
is excited at 490 nm resulting in the emission apple green colour which can be viewed 
under a fluorescent microscope. 
 
The slides were washed in briefly in TBS-Tween for 5 minutes followed by incubation in 
TNB for 30 minutes at 37 ºC. The slides were then incubated in 75 µl of anti-DIG IgG 
conjugated with FITC diluted 1:500 in TBS-Tween for 30 minutes at 37 ºC. Thereafter 
the slides were washed in TBS-Tween for 15 minutes (3 changes of 5 minutes each). The 
slides were then mounted with SlowFade Light Antifade Kit (Molecular Probes) and the 
   60 
 
manufacture’s instructions were followed. A drop of component C which is an 
equilibration buffer was placed on the section each section and incubated at RT for 10 
minutes or until dry. Then a drop of component A was placed on the each section and 
covered with a coverslip. The slides were viewed immediately under fluorescent 
microscope and images captured using Zeiss Microscope Camera and Axio software 
package.   
 
2.4. Real Time Polymerase Chain Reaction 
Real Time Polymerase Chain Reaction (RT-PCR) was developed because of a need to 
quantitate differences in mRNA expression. It quantitates the initial amount of the 
template most specifically, sensitively and reproducibly as it monitors the real-time 
progress of PCR and is a preferable alternative to other forms of quantitative RT-PCR as 
they detect the amount of final amplified product at the end point (Freeman, 1999). RT-
PCR can be used to calculate the number of particles e.g. viral copy in a given amount of 
blood or the fold difference of a target nucleic acid in an equivalent amount of tests and 
control samples. These analysis methods are referred to as absolute and relative 
quantification respectively.  
The RT-PCR system is based on the fluorescence reporter. RT-PCR monitors the 
fluorescence emitted during the reaction as an indicator of amplicon production during 
each PCR cycle (i.e. Real Time) as opposed to the end point detection (Huguchi, 1993). 
This signal increases in direct proportion to the amount of PCR product formed after 
every cycle. Initially fluorescence remains at the background levels and increases in 
fluorescence are not detectable even though product accumulates exponentially. 
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Eventually enough amplified product accumulates to yield a detectable fluorescence 
signal. The cycle at which this occurs is called the threshold cycle (CT) which is defined 
as the cycle at which the fluorescence emission exceeds the fixed threshold. The use of 
threshold cycle (CT) value makes RT-PCR to be more precise. Fluorescence values are 
recorded during every cycle and represent the amount of product amplified to that point 
in the amplification reaction. The more templates present at the beginning of the reaction, 
the fewer number of cycles it takes to reach a point in which the fluorescent signal is first 
recorded as statistically significant above background. CT value measured during the 3-15 
cycles indicates the detection of accumulated PCR product. A CT value of 40 or higher 
means no amplification and this value cannot be used for calculations. 
SYBR Green is one of the fluorescence reporter used in Real Time PCR. Its chemistry 
provides the simplest format for detecting and quantitating PCR products in real time 
reactions. SYBR Green is a dye that binds the minor grooves of a double stranded DNA. 
When SYBR Green dye binds to a double stranded DNA, the intensity of the 
fluorescence emission increases. As more double stranded amplicons are produced, 
SYBR Green dye signal will increase. Thus, as a PCR product accumulates, the 
fluorescence increases.  
The disadvantage of SYBR Green dye is that it binds to any double stranded DNA in the 
reaction including primer-dimers and other non-specific reaction products, which results 
in the overestimation of the target concentrations. For that reason SYBR green reactions 
should be optimised to be sensitive and specific. Amplicon size must also be optimised. 
Shorter amplicons of about 75-200 bp are typically amplified with higher efficiency. 
Beacon Designer software performs both primer design and amplicon selection. The 
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efficiency and the reproducibility of a SYBR Green assay can be determined by 
constructing a standard curve using serial dilutions of known template. The efficiency 
should be 90-105 %. Coefficient of determination (R
2
) can also be used to evaluate 
whether the RT-PCR is optimised. R
2
 value of a standard curve represents how well the 
experimental data fit the regression line (i.e. how linear the data is). R
2
 Value should be 
greater than 0.980 for quantitative RT-PCR reactions. Melting curves are used to check 
for the specificity of the primers. Non-specificity of the primers can be detected by 
multiple picks on the melting curve. 
Bio-Rad MJ Mini-Opticon Personal Thermal Cycler (Bio-Rad Laboratories, Hercules, 
CA, USA) was used to run the quantitative Real Time PCR (qRT-PCR). Primers were 
designed using Beacon Designer software and sequences are as tabulated in table 2.8. 
RNA was extracted from MRC5 and A549 cell lines as described in section 2.2.1 and 
cDNA synthesised using ImProm-II
TM
 Reverse Transcription (Promega Corporation, 
Madison, WI, USA). Manufacturer’s protocol was followed and the reaction carried out 
as described in section 2.2.3. cDNA was diluted 20 times (1 µl cDNA + 19 µl sdH2O) 
and quantified using a spectrophotometer (Amersham Pharmacia Biotech, Picataway, NJ, 
USA) at 260 nm and the following equation was used to calculate cDNA concentration: 
c = A260 x [A260 ds DNA] x DF 
A260 ds DNA = 50 µg/ml 
DF = 20  
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Table 2.8: Primer sequences used for Relative qRT-PCR 
Gene  Primer   Sequence (5’ to 3’)   
RPL9  Forward  ttacactgggcttccgttac   
   Reverse  gcaacacctggtctcatcc 
LIAS  Forward  ttcgtgaggcagatgtagac 
   Reverse  tatatgaagaacgcaccaaagg 
2.4.1. Optimisation of primers 
Temperature gradient was run to optimise the annealing temperature of the primers 
followed by a melting curve analysis to assess the specificity of the primers.  
 
Table 2.9: Reaction components for primer optimization 
Reagent Volume Final Concentration 
iQ
TM
SYBR Green Mix I 
(Bio-Rad Laboratories, 
Hercules, CA,USA) 
12.5 µl 1 X 
Forward Primer 1 µl 0.4 ρmol/ µl 
Reverse Primer 1 µl 0.4 ρmol/ µl 
cDNA  x 1 µg 
sdH2O y   
Total Volume 25 µl  
x and y - Variable depending on the concentration of the template (cDNA). 
Conditions: 
Activation:  94 
oC…………5 minutes 
Amplification: Denaturation:  94
 oC………... 30 seconds 
Annealing:       55-59
 oC …….30 seconds  
40 cycles 
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Extension: 72 
oC………... 30 seconds    
Plate read 
Final Extension 72
 o
C ……... 10 minutes  
Melting temperature analysis: 55-99
 o
C – 1 o increment, hold for 10 seconds at 
each temperature 
    
2.4.2. Standard curve generation 
To assess the amplification efficiency of Quantitative Real Time PCR, serial dilutions of 
the cDNA were used to generate standard curves. Five fold dilution series of the cDNA 
were made as tabulated in table 2.10.  
 
Table 2.10: cDNA Dilutions for generating a standard curve. 
Dilution Concentration Volume cDNA 
1 X 1135 ng/µl 1 µl 
5 X 227 ng/µl 1 µl 1X + 4 µl sdH2O 
25 X 45.8 ng/µl 1 µl 5X + 4 µl sdH2O 
125 X 9.08 ng/µl 1 µl 25X = 4 µl sdH2O 
 
 
Following the serial dilutions qRT-PCR was run. iQ
TM
 SYBR Green I Mix (Bio-Rad 
Laboratories, Hercules, CA, USA) was used and the reagents components are as in table 
2.11. 
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Table 2.11: Reagent component for the standard curve  
Reagent Volume Final Concentration 
iQ
TM
SYBR Green Mix I 
(Bio-Rad Laboratories, 
Hercules, CA,USA) 
12.5 µl 1 X 
Forward Primer 1 µl 0.4 ρmol/ µl 
Reverse Primer 1 µl 0.4 ρmol/ µl 
cDNA (1 X, 5 X, 25 X, 125 
X) 
1 µl 1135 ng, 227 ng, 45.4 ng, 
9.08 ng 
sdH2O 9.5 µl  
Total Volume 25 µl  
 
Conditions: 
Activation:  94 °C…………5 minutes 
Amplification: Denaturation:  94 °C………... 30 seconds 
Annealing:  57 °C LIAS/… 30 seconds  
58 °C RPL9… 30 seconds       40 cycles 
Extension: 72 °C………... 30 seconds    
Plate read 
Final Extension 72 °C ……... 10 minutes  
 
Amplification Efficiency (E) of the assay was calculated from slope of the standard curve 
and converted to % Efficiency using the following formulas: 
E = 10
-1/slope
 
% E = (E-1) x 100 % 
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2.4.3. Relative quantitative Real Time Polymerase Chain Reaction 
After the efficiency and annealing temperature of the primers were optimised, relative 
qRT-PCR normalised against the unit mass was carried out. MRC5 was used as a 
calibrator and A549 as a test. 
Table 2.12: Relative qRT-PCR reaction components 
Reagent Volume Final Concentration 
iQ
TM
SYBR Green Mix I 
(Bio-Rad Laboratories, 
Hercules, CA,USA) 
12.5 µl 1 X 
Forward Primer 1 µl 0.4 ρmol/ µl 
Reverse Primer 1 µl 0.4 ρmol/ µl 
cDNA  x 1 µg 
sdH2O y µl  
Total Volume 25 µl  
x and y - Variable depending on the concentration of the template (cDNA). 
 
Conditions: 
Activation:  94°C…………5 minutes 
Amplification: Denaturation:  94 °C………... 30 seconds 
Annealing:  57 °C LIAS/… 30 seconds  
58 °C RPL9… 30 seconds       40 cycles 
Extension: 72 °C………... 30 seconds    
Plate read 
Final Extension 72 °C ……... 10 minutes  
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The following equation was used to calculate the ratio of expression of RPL9 and LIAS 
in lung adernocarcinoma A549 (Test) relative to lung normal fibroblast MRC5 
(calibrator) 
Ratio(test/calibrator) = E 
CT (calibrator) – CT(test)TM 
 
2.5. TUNEL 
One of the changes that occur during apoptosis is nuclear fragmentation which results in 
a large number of DNA fragments. These fragments can be detected by labelled 3’ OH 
termini with biotin. The reaction is catalysed by exogenous terminal deoxynucleotide 
transferase (Tdt). Streptavidin labelled with horse-peroxidase (HRP) is bound to these 
nucleotides and in the presence of diaminobenzidine (DAB), apoptotic nuclei are stained 
dark brown.  
 
The Promega DeadEnd
TM
 colorimetric TUNEL system kit (Promega Corporation, 
Madison, WI, USA) was used. Sections were dewaxed in two changes of xylem for ten 
minutes each. The sections were then rehydraded in two changes of fresh absolute 
ethanol for five minutes each. This was followed by a further rehydration in 95 %, 85 %, 
70 % and 50 % ethanol for three minutes each. The sections were washed with 0.85 % 
sodium chloride for five minutes followed by a wash in 1% PBS for five minutes. 
Sections were fixed in 4 % PFA for 15 minutes followed by three washes in PBS for 
three minutes each. 100 µl of Proteinase K (Roche diagnostics, Germany) (20µg/µl) 
diluted 1:500 with PBS was added to each section and incubated for 20 minutes. This was 
washed off by immersing the sections in PBS for five minutes. The sections were 
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immersed in 4% PFA for five minutes and then washed in two changes of PBS for five 
minutes each. 100 µl of equilibration buffer was added to each slide for ten minutes. 1 µl 
of bionylated mix and 1 µl of Tdt enzyme were added to 98 µl of equilibrated buffer. 100 
µl of the mix was added to each slide and incubated fro an hour in a humidity chamber at 
37 °C. The sections were then immersed in 2X SSC for 15 minutes followed by three 
changes of PBS for five minutes each. 100 µl of 0.3 % hydrogen peroxidase was added to 
each section and incubated for five minutes. The sections were washed in three changes 
of PBS for five minutes each. 100 µl streptavidin HRP diluted 1:500 in PBS was added to 
each section and incubated for 30 minutes. After the incubation the sections were 
immersed in three changes of PBS for five minutes each. 100 µl of the prepared DAB 
solution was added to each section and incubated until a light brown colour developed. 
The sections were rinsed in three changes of deionised water followed by dehydration in 
50 %, 70 %, 85 % and 95 % ethanol for one minute each. They were further dehydrated 
in two changes of absolute ethanol for one minute each and immersed in xylene for one 
minute. The slides were mounted in xylene-based entellan and viewed under a light 
microscope. The Zeiss camera and Axio software package were used to capture the 
images.  
 
2.5.1. Controls 
For a negative control, Tdt was not added to the sections and for a positive control the 
sections were treated with DNAse to allow for a fragmentation of the DNA.  
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2.6. Bioinformatics 
To study the interaction of RPL9 and LIAS with other proteins, the Bioinformatics tool 
BONDplus (Biomolecular Network Database plus) was used. The software interact 
GENESEQ
TM
 and BINDplus to explain all the relevant biological relationships of the 
molecule of interest. GENESEQ
TM
 contains high quality easy to understand annotated 
genetic patented sequences covering genetic discovery. BINDplus contains prominent as 
well as the latest published low throughput and high throughput interactions documented 
according to rigorous data curation standards.  
Gene Identification (Gene ID) for RPL9 and LIAS were obtained from the National 
Centre for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov). 
The Gene ID was used on the BONDplus database to search for any interaction 
discoveries of the two genes. 
 
2.6.1. Gene Conservation 
To assess the conservation of RPL9 and LIAS through species, NCBI database was used 
to retrieve gene homologues of the genes under investigation. Protein sequences in 
FASTA format of the closest to RPL9 and LIAS by species were retrieved and aligned 
using CLUSTAL 2.0.3 multiple alignment software.   
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3. Results  
3.1. Expression of LIAS and RPL9 in human lung cancer. 
3.1.1. In Situ hybridization 
Localization of RPL9 and LIAS RNA was achieved by the fluorescence and colorimetric 
detection of anti-sense DIG-labelled RNA probes. Anti-DIG conjugated alkaline 
phosphatase was used for colorimetric detection of the DIG labelled anti-sense probes in 
the presence of the substrate NBT/BCIP while anti-DIG conjugated FITC was used for 
fluorescence detection. The enzymatic activity of NBT/BCIP substrate and alkaline 
phosphatase conjugated anti-DIG results in a purple/blue precipitate. FITC does not 
require the presence of a substrate; it emits an apple green light when excited at a 
wavelength of 490nm. The expression of RPL9 and LIAS was determined by comparing 
tissue sections localised with a DIG-labelled anti-sense probe to those labelled with a 
DIG labelled sense probes. The following steps were done for in situ hybridization.  
  
3.1.1.1. RNA extraction 
Total RNA was extracted using the Trizol
TM
LS reagent method (section 2.3.1) and the 
quality of the extracted RNA was analysed on 1% (w/v) formaldehyde agarose gel 
electrophoresis (section 2.3.2).  
 
3.1.1.2. Polymerase Chain Reaction 
RNA obtained was used to synthesis cDNA by reverse transcription PCR as described in 
section 2.3.3. Synthesised cDNA was used as a template to amplify 165 bp RPL9 and 190 
bp LIAS region of interest using gene specific primers (section 2.3.4 and 2.3.5). The 
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results were analysed on 0.1 % agarose gel electrophoresis (Figure 3-6). RPL9 and LAIS 
amplified bands were found to be 165 bp (lane 4-7) and 190 bp (lane 8-12) long 
respectively. cDNA was substituted by nuclease free H2O in the negative control and the 
results were positive as no band is observed in negative control lane (lane 2 for RPL9 and 
lane 3 for LIAS).  
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Polymerase Chain Reaction 
Lane 1 indicates the molecular weight marker. Lane 2 represents the negative control for RPL9 and lane 3 
LIAS were cDNA was replaced by nuclease free  H2O. Lane 4-7 represents the amplification of RPL9 
while lane 8-12 represents the amplification of LIAS. 
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3.1.1.3. Cloning of RPL9 and LIAS into p-GEM T Easy 
As described in section 2.3.8 PCR products of RPL9 and LIAS were ligated into p-GEM 
T Easy cloning vector that contains the 3’-T overhangs which allows for easy ligation 
with Poly (A) Tail of PCR product, the multiple cloning site for restriction digestions and 
the ampicillin resistant domain used as a selective markers. Ligated clones were 
transformed into MC1061 E. coli competent cell  
 
3.1.1.4. Colony PCR 
After cloning positive colonies were selected by colony PCR. Colonies were randomly 
selected on the ampicillin nutrient agar plates and resuspended in 10µl sdH2O. The 
colony mix was used as a template and the region of interest amplified using LIAS and 
RPL9 specific genes. Results were analysed on 0.8% agarose (Figure 3-7). The insert was 
present and was found to be the right size for both RPL9 and LIAS, 165 bp and 190 bp 
long respectively as expected figure. 
 
 
 
 
 
 
 
Figure 3-2: Colony Polymerase Chain Reaction 
Lane 1 indicate the molecular weight marker. Lane 2-9 shows the presents of LIAS insert from colonies 
randomly selected from NA-ampicillin plate while lane 10-18 indicates the presents of RPL9 insert. 
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3.1.1.5. Plasmid DNA extraction and sequencing 
Positive colonies which were selected by the presence of the insert by colony PCR were 
used to inoculate an overnight culture. Plasmid DNA was extracted using the 
WizardPlus® SV Miniprep Purification System (Promega Corporation, Madison, WI, 
USA). The purified LIAS and RPL9 recombinant clones were sent to Inqaba biotechnical 
Industries (RSA) for sequencing to check if the inserts were present, if they were the right 
sequence and to also check the orientation of the insert.  The results showed that the 
correct insert for both RPL9 and LIAS was present in the recombinant plasmid DNA. 
This is indicated by the sequence alignment using the reference sequences for RPL9 and 
LIAS obtained from the National Centre for Biotechnology Information (Figure 3-8). 
After confirmation of the presence of the correct cloned, the recombinant plasmid DNA 
was extracted for probe synthesis.   
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Keywords: Query -Reference sequence; Sbjct -Recombinant sequence  
Figure 3-3. Sequence alignment of RPL9 and LIAS genes 
The clone sequences obtained from Inqaba Biotech was aligned to reference sequences for RPL9 
(accession number: BC100285) and LIAS (accession number: BC062751) attained from National Centre 
for Biomedical Information (NCBI). Both RPL9 (A) and LIAS (B) cloned sequences were found to be 
100% identical to their specific reference sequence. The length of the sequences also corresponded with the 
predicted which was 165bp and 190bp long for RPL9 and LIAS respectively (Table 2.2) 
 
 
 
 
 
 Score =  317 bits (165),  Expect = 2e-83 
 Identities = 165/165 (100%), Gaps = 0/165 (0%) 
 Strand=Plus/Plus 
 
Query  18   CTCCGGGTTGACAAATGGTGGGGTAACAGAAAGGAACTGGCTACCGTTCGGACTATTTGT  77 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  222  CTCCGGGTTGACAAATGGTGGGGTAACAGAAAGGAACTGGCTACCGTTCGGACTATTTGT  281 
 
Query  78   AGTCATGTACAGAACATGATCAAGGGTGTTACACTGGGCTTCCGTTACAAGATGAGGTCT  137 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  282  AGTCATGTACAGAACATGATCAAGGGTGTTACACTGGGCTTCCGTTACAAGATGAGGTCT  341 
 
Query  138  GTGTATGCTCACTTCCCCATCAACGTTGTTATCCAGGAGAATGGG  182 
            ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  342  GTGTATGCTCACTTCCCCATCAACGTTGTTATCCAGGAGAATGGG  386 
 
       
 
 
 
 
 Score =  365 bits (190),  Expect = 8e-98 
 Identities = 190/190 (100%), Gaps = 0/190 (0%) 
 Strand=Plus/Minus 
 
Query  45   ACAAGGATTTTTGGATTCCTTTCCTTTAAATATGATACGGTCTTTGCAATGTGTTCAGCT  104 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  699  ACAAGGATTTTTGGATTCCTTTCCTTTAAATATGATACGGTCTTTGCAATGTGTTCAGCT  640 
 
Query  105  CCCCCATCAGGCATATCATCTCGATCCACAGATGTCAGGACAACATAATCCAGACCCCAT  164 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  639  CCCCCATCAGGCATATCATCTCGATCCACAGATGTCAGGACAACATAATCCAGACCCCAT  580 
 
Query  165  TCTGCAATTGCCTTTGCAGTATTGTAGGGCTCACTGGCATCCAGTGGAGGAGGATTTCTT  224 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  579  TCTGCAATTGCCTTTGCAGTATTGTAGGGCTCACTGGCATCCAGTGGAGGAGGATTTCTT  520 
 
Query  225  GCAGTCTTAA  234 
            |||||||||| 
Sbjct  519  GCAGTCTTAA  510 
 
 
     
 
 
 
A 
B 
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Figure 3-4: Plasmid DNA extraction 
Lane 1 indicates molecular weight marker. Lane 2-4 represents a RPL9 clone while lane 5-7 represents 
LIAS clone. The variable band sizes indicate the different states of the plasmid that varies from tightly 
coiled to completely relaxed.  
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3.1.1.6. Linearisation of clones and DIG labeling of probes 
The purified clone containing the correct gene and sequence was used as a template for 
synthesis on DIG labeled probes. PstI was used to generate an anti-sense probe while 
ApaI was used to generate the sense probe. Figure 3-5 and Figure 3-6 shows the 
linearization of RPL9 and LIAS clones respectively. The linearised clones (lane 3 and 
lane 4) were purified from the agarose gel and used as templates for probe synthesis.  
 
 
 
Figure 3-5: Restriction digestion RPL9 clone 
Lane 1 shows the DNA molecular weight marker. Lane 2 represents the undigested clone. Lane 3 is the 
clone digested with Pst1 while in lane 4 is the clone digested with Apa1 
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Figure 3-6: Restriction digestion of LIAS clone 
Lane 1 represent DNA molecular weight marker. Lane 2 is the undigested clone. Lane 3 is the clone 
digested with Pst1 while lane 4 is the clone digested with Apa1.  
 
3.1.1.7. Ribosomal Protein L9 and Lipoic Acid Synthetase genes localisation 
Localization of RPL9 and LIAS RNA was achieved by the fluorescence and colorimetric 
detection of an anti-sense DIG-labelled RNA probes. Anti-DIG conjugated alkaline 
phosphatase was used for colorimetric detection of the DIG labelled anti-sense probes in 
the presence of the substrate NBT/BCIP while anti-DIG conjugated FICT was used for 
fluorescence detection. The enzymatic activity of NBT/BCIP substrate and alkaline 
phosphatase conjugated anti-DIG results in a purple/blue precipitate. FITC does not 
require the presence of a substrate; it emits an apple green light when excited at a 
wavelength of 490nm.  
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Figure 3-7: Localisation of RPL9 mRNA in Squamous Cell Lung Carcinoma  
(A) and (B) represents the negative control, localisation with sense probe which shows no expression of RPL9. In all the three grades of the squamous cell lung 
carcinoma (C and D, poor differentiated; E and F, moderately differentiated; and G well differentiated) RPL9 mRNA in expressed in the cytoplasm of the type I 
pneumocytes (I). RPL9 is also expressed in the cytoplasm of the lymphocytes L and Macrophages M. (Magnification 400X) 
  L 
I 
M 
(A) (G) (E) (C) 
(D) (F) (B) 
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Figure 3-8: Localisation of RPL9 mRNA in Small Cell Lung Carcinoma 
(A) and (B) represents the negative control, localisation with sense probe which shows no expression of 
RPL9. RPL9 is expressed in the cytoplasm of the small cell lung carcinoma tumour cell (C and D) which 
resembles the lymphocytes. (400X Magnification) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
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Figure 3-9: Localisation of RPL9 mRNA in Large Cell Lung Carcinoma 
(A) and (B) represents the negative control, localisation with sense probe which shows no expression of 
RPL9. C and D show a high expression of RPL9 in the cytoplasm of the tumour cells and fibres in the 
surrounding stroma. The cells show no defined pattern between Squamous Cell lung Carcinoma and Lung 
Adenocarcinoma which is a principle characteristic of Large Cell Lung Carcinoma. (Magnification 400X)  
 
(A) (B) 
(C) (D) 
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Figure 3-10: Localisation of RPL9 mRNA in Lung Adenocarcinoma 
(A and B) represents the negative control, localisation with sense probe which shows no expression of RPL9. RPL9 is localised by a sense probe in the different 
grades of the tumour tissue. Grade I, poor differentiated (C and D); Grade II, moderately differentiated (E and F) and Grade III, well differentiated (G and H). 
RPL9 mRNA is expressed in the cytoplasm of the columnar ciliated cells of the bronchial gland G which is clearly represented in the moderately differentiated 
grade (E and F). As the tumour progresses, cells tend to grow in sheets (G and H). (Magnification 400X) 
G 
(A) (C) (E) (G) 
(B) (D) (F)   (H) 
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Figure 3-11: Localisation of LIAS in Squamous Cell Lung Carcinoma 
 
(A and B) represents the negative control, localisation with sense probe which shows no expression of 
RPL9. The results show localisation of LIAS in the cytoplasm of tumour cells. The arrangement of cells in 
broad sheets and large nests N indicate a major characteristic of squamous cell carcinoma. (Magnification 
400X).  
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Figure 3-12: Localisation of LIAS mRNA in Lung Adenocarcinoma 
A and B represents negative control which is localisation with sense probe. The poorly differentiated (C 
and D) grade shows a poorly formed glandular structure. The well differentiated (E and F) shows the 
glands composed of tall columnar epithelium with ample cytoplasm and basally situated nuclei. LIAS 
mRNA is localised in the cytoplasm of the columnar epithelial cells in the poorly and well differentiated 
grades. (Magnification 400X)  
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Figure 3-13: Localisation of LIAS mRNA in Small Cell Lung Carcinoma 
(A) and (B) represents a negative control, which is a localisation of LIAS mRNA with a sense strand and it 
shows no expression of LIAS mRNA. In the Small Cell Lung Carcinoma tissue (C and D), LIAS is 
expressed in the cytoplasm of the tumour cells that resembles lymphocytes. (Magnification 400X) 
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Summary 
 
The expression of RPL9 and LIAS was done by comparing localisation of RPL9 and 
LIAS mRNA in lung cancerous and normal tissues with the anti-sense probe to the 
negative control which is the localisation with the sense probe.  Both are expressed in 
normal and cancerous tissues but the expression is lower in normal tissue compared to 
cancerous tissue. Observation of the tissue indicated that the expression of RPL9 
increases with the progression from poor to well differentiated of the adenocarcinoma 
and squamous cell carcinoma, figure 3-10 and 3-09 respectively. The expression is the 
highest in small cell lung carcinoma (figure 3-8) followed by adenocarcinoma, squamous 
cell lung carcinoma and the lowest in large cell lung carcinoma (figure 3-09). The 
expression of LIAS increased with the progression of squamous cell lung carcinoma as 
shown in figure 3-11 and decreased in the progression of adenocarcinoma from poor to 
well differentiated (figure 3-12). However the expression of LIAS was the highest in 
adenorcarcinoma, followed by squamous cell carcinoma and the lowest in small cell 
carcinoma (figure 3-13). The overall expression of RPL9 is relatively higher than LIAS 
in lung normal tissue and lung cancer.   
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3.2. Real Time Polymerase Chain Reaction 
Real Time PCR was used to quantify the expression level of RPL9 and LIAS in lung 
cancer. RNA was extracted from lung adenocarcinoma (A549) and lung normal 
fribroblast (MRC5) cell lines. mRNA from both cell lines was reverse transcribed into 
cDNA using reverse transcriptase and oligo-(dT)15 primers. cDNA was used as a 
template for the Real Time PCR using SYBR Green I and the gene specific primers. 
Standard curves, melting curves and quantitation curves were used to analyse the results 
using the Opticon 3.1 software. 
  
3.2.1. Assessment of assay efficiency and optimisation using standard curves 
In order to assess the efficiency of the assay, standard curves for the genes under 
investigation were constructed using serial dilutions of template DNA. The standard 
curves were constructed by plotting the log of the starting template concentration against 
the threshold cycle (CT) obtained from the amplification of each dilution. Amplification 
efficiency was calculated using the slope obtained from the standard curve using the 
following formula: 
 E (Efficiency) = 10
-1/slope 
Amplification efficiency can also be converted into percentage efficiency by using the 
formula: 
% Efficiency = (E-1) x 100% 
 
Five fold dilution series of the cDNA was used as a standard template.  
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Calculation: 
 
 
LIAS 
  Slope = -3.38 
      E  = 10
-1/slope 
 =1.97 
%Efficiency = (E-1) x 100% 
          = 97% 
 
RPL9 
Slope = -3.35 
      E  = 10
-1/slope 
 = 1.98 
%Efficiency = (E-1) x 100% 
         = 98% 
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Figure 3-14: RPL9 standard curve to assess the efficiency of the reaction assay. 
Amplification curve (A) for RPL9 gene using SYBR Green I dye illustrate equidistance between the five 
fold dilution series of the DNA extracted from MRC5 cell line. Standard curve CT values obtained from the 
amplification curve plotted against the Log concentration of the template starting quantity for each 
dilution. The slope of the curve was found to be -3.35 and the efficiency was 98% 
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Figure 3-15: LIAS standard curve generated to assess the efficiency of the reaction 
assay. Amplification curve (A) for LIAS gene using SYBR Green I dye illustrate equidistance between 
five fold dilution of the starting quantity of the template cDNA. CT values obtained from the amplification 
curve were plotted against the Log concentrations for all the dilutions to generate a standard curve. The 
calculated PCR efficiency using the slope (-3.38) of the curve was 97%  
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3.2.2. Melting curves for RPL9 and LIAS 
Melting curves were plotted and used to assess for the presence of multi-products due to 
the presence of contaminating DNA, presence of primer dimers or the non-specificity of 
the primers. The quantified product was allowed to melt at a constant increase in 
temperature of 1°C and allowed to hold for 30 seconds from 55 °C to 99°C.  The 
presence of single peak signifies the presence of single identical product. The presence of 
multi-products will be indicated by multi peaks and same applies with primer dimmers. 
Since elimination of primer dimers is very crucial for the accuracy of real time PCR 
using SYBR Green dye, melting curves presents a very useful tool for gene expression 
analysis.   
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Figure 3-16: Annealing temperature optimization and melting curve to analyse the 
specificity of RPL9 primers 
 
In order to optimise the annealing temperature of the primers, a temperature gradient (52 – 59 oC) with 
replicates of concentrations was run. The primers showed to be optimum at 58
 o
C (     ). The curve shows 
the specificity of the primers which is observed by a single peak with a melting temperature of 81°C in all 
the replicates. The blank (    ) shows no primer dimmers or contamination with foreign DNA as no peak is 
observed. 
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Figure 3-17: Annealing temperature optimization and melting curve to analyse the 
specificity of LIAS primers 
A temperature gradient (52-59
o
C) was run and LIAS primers are optimum at 57
o
C (     ). The curve shows 
the specificity of the primers which is observed by a single peak with a melting temperature of 80°C in all 
concentration replicates. The blank (      ) shows no contamination with foreign DNA or primer dimmers as 
no peak is observed. 
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3.2.3. Relative Quantitative Real Time Polymerase reaction of RPL9 and LIAS expression 
normalised against unit mass 
Relative quantification is used to compare an expression level of a gene between a test 
and calibrator, e.g. cancerous and normal cells of the same tissue as opposed to absolute 
quantification that measures the number of particles in a given amount of sample. The 
system monitors the fluorescence emitted during the reaction as an indicator of amplicon 
production during each cycle. The threshold cycle (CT) is recorded as the cycle at which 
fluorescence emission exceeds the fixed threshold. The lower the CT value of the test 
(cancerous cells) relative to the calibrator (normal cells) the higher the templates present 
at the beginning of the reaction and the higher the CT value the lower the template 
(Section 2.4). When running relative qRT-PCR that is normalised against unit mass, 
quantity/ concentration of the starting template must be equal. cDNA was synthesized 
using RNA extracted from MRC5 and A549 cell lines. cDNA was quantified using a 
spectrophotometer at A260 and 1µg MRC5 and 1µg A549 cDNA was used as a starting 
material.  
 
MRC5:          A549: 
A260 = 1.494      A260  = 1.787 
DF    = 20       DF   = 20    
A260 ds DNA = 50 µg/ ml    A260 ds DNA = 50 µg/ ml 
[MRC5] = A260 x[A260 ds DNA] xDF  [A549] = A260 x [A260 ds DNA] x DF 
   = 1.494 µg/ µl    = 1.787µg/ µl 
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Figure 3-18: Quantification curve for LIAS 
The above figure illustrate the expression level of LIAS in lung adernocarcinoma A549 
(      ) relative to lung normal fibroblast MRC5 (     ). CT values for A549 and MRC5 is 
24.4 and 26.5 respectively. Using the ratio equation described in section 2.4.3 with the 
amplification efficiency of 1.97, the expression of LIAS is 4 fold upregulated in A549 
than in MRC5. In the blank (       ) template was replaced with sdH2O. 
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Figure 3-19: Quantification curve for RPL9 
The figure above illustrate the expression level of RPL9 in lung adernocarcinoma A549 
(      ) relative to lung normal fibroblast MRC5 (     ) normalised against a unit mass. CT 
values for A549 and MRC5 is 15.05 and 18.07 respectively. Using amplification 
efficiency of 1.98, the expression of RPL9 is 8 fold upregulated in A549 than in MRC5. 
In the blank (       ) template was replaced with sdH2O and it doesn’t show any trace of 
contaminating DNA . 
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Summary 
RPL9 and LIAS gene specific primers designed with the Beacon Designer Software 
showed to be highly efficient which was demonstrated by the standard curves. The 
efficiency of LIAS and RPL9 were calculated to be 97% and 98% respectively (Figure 3-
14 and Figure 3-15) which is within the accepted range of primer efficiency of 90-105%. 
The efficiencies demonstrate that for every cycle of the real time PCR, the starting 
amount of template is doubled which is the main principle behind every PCR protocol.  
 
Melting curves were utilised to analyse the specificity of the primers and this is observed 
by the peaks on the curve. The results are represented as a graph of relative fluorescence 
over time (-dT/dTmax) versus temperature. Melting curves for both genes under 
investigation showed specificity of the primers which was observed by a single peak. 
Melting temperature for LIAS and RPL9 was 80
o
C and 81
o
C respectively as indicated in 
Figure 3-16 and Figure 3-17.  
 
Using a unit mass as a normaliser RPL9 and LIAS were quantified. RNA was extracted 
from fresh MRC5 and A549 cell lines. RNA was used to make up cDNA by reverse 
transcription and quantified by spectrophotometer. One µg of the cDNA was used as a 
template for real time PCR.  
Using the equation:  Ratio(test/calibrator) = E 
CT (calibrator) – CT(test)
 the ratio of expression of 
RPL9 and LIAS in lung adenocarcinoma relative to normal lung was determined. LIAS 
was found to be 4 fold up-regulated in lung adenocarcinoma while RPL9 was found to be 
8 fold up-regulated (Figure 3-18 and Figure 3-19).  
   97 
 
3.3. TUNEL 
The terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate biotin 
nick-end labeling (TUNEL) was applied to visualize where in the tissue apoptosis was 
occurring. During apoptosis, one of the morphological changes observed in the nuclei of 
apoptotic cells is the formation of DNA fragmnets in the region of 180 to 200 base pairs. 
The DeadEnd
TM
 colorimetric TUNEL system adds biotinylated deoxyuridine at the 3’ –
OH DNA ends of each fragment by the nontemplate-dependent DNA polymerase, 
Terminal deoxynucleotidyl Transferase (TdT). Horseradish-peroxidase-labelled 
streptavidin binds to the biotinylated nucleotides and a subsequent addition of peroxidase 
substrate, hydrogen peroxide and diaminobenzidine (DAB) chromogen result in apoptotic 
nuclei staining dark brown.  
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Figure 3-20: Apoptosis detection by TUNEL in lung cancer 
TUNEL representation in (A) adenocarcinoma, (B) large cell carcinoma, (C) squamous cell carcinoma and 
(D) Mesothilia. E represents a negative control. Magnification 400X.  
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Summary 
The TUNEL method labels DNA fragments and is therefore an effective technique for 
apoptosis detection. Fragmentation of the DNA was observed in the cytoplasm and is the 
highest in adenocarcinoma. By comparing the results obtained from In situ Hybridization 
and Real Time PCR it can be concluded that apoptosis occurs in the same regions and the 
same pattern as the expression level of RPL9 mRNA. Localisation of RPL9 mRNA was 
the highest in adenocarcinoma, followed by squamous cell carcinoma and then large cell 
carcinoma. The pattern of apoptosis is observed in lung cancer. This association is the 
same with LIAS expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   100
 
3.4. Bioinformatics 
3.4.1. Gene Conservation 
For gene conservation through species, NCBI was used to check for human RPL9 and 
LIAS gene homologues. The amino acid sequences of the closest species to that of 
human were retrieved from NCBI and pair-wise alignment done using CLUSTALW 
2.0.3 multiple sequence alignment software. The search results were as shown below  
 
3.4.1.1. Lipoic Acid Synthetase CLUSTALW 2.0.3 multiple sequence alignment 
 
 
The results are presented as scores that indicate percentage similarities between two 
sequences. Human (Homo sapiens) LIAS is most identical to that of Rat (Rattus 
norvegicus) with a percentage similarity score of 91. This is followed by mouse (Mus 
musculus) with 90% score similarity. Human LIAS is least similar to Drosophila with a 
61% score similarity. 
 
 
Sequence 1: gi|37577166|ref|NP_006850.2|     372 aa (Homo sapiens) 
Sequence 2: gi|13277380|ref|NP_077791.1|     373 aa (Mus musculus) 
Sequence 3: gi|58865650|ref|NP_001012037.1   373 aa (Rattus norvegicus) 
Sequence 4: gi|17737685|ref|NP_524183.1|     380 aa (Drosophila) 
 
Pair-wise alignment 
 
Sequences (1:2) Aligned. Score:  90 
Sequences (1:3) Aligned. Score:  91 
Sequences (1:4) Aligned. Score:  61 
Sequences (2:3) Aligned. Score:  95 
Sequences (2:4) Aligned. Score:  61 
Sequences (3:4) Aligned. Score:  61 
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Mouse  --MALRCWDTARSLGSRIFGRYAFT-VRALSSLPDKKKEFLHNGPDLQDF 47 
Rattus --MALRCWDAARSLGSRIFGRYACS-VRALSSLPDEKKKFLHNGPDLQDF 47 
Human  --MSLRCGDAARTLGPRVFGRYFCSPVRPLSSLPDKKKELLQNGPDLQDF 48 
Drosophila MYVMLRALKTHAEAPIVVATRAASTNAEKLEEIRER----LAKGPNFHDF 46 
  : **. .:       :  *   : .. *..: :.    * :**:::** 
 
Mouse  VSGDLADKSTWDEYKGNLKRQKGE--RLRLPPWLKTKIPMGKNYNKLKNT 95 
Rattus VSGDLADKSTWDDYKGNLKRQKGE--RLRLPPWLKTKIPMGKNYNKLKNT 95 
Human  VSGDLADRSTWDEYKGNLKRQKGE--RLRLPPWLKTEIPMGKNYNKLKNT 96 
Drosophila VQNPDNTRNEWEQYDGKLRREKGEEQRLRLPPWLKTTIPVGKNYAKIKAQ 96 
  *..    :. *::*.*:*:*:***  ********** **:**** *:*   
 
Mouse  LRNLSLHTVCEEARCPNIGECWGGGEYATATATIMLMGDTCTRGCRFCSV 145 
Rattus LRNLNLHTVCEEARCPNIGECWGGGEYATATATIMLMGDTCTRGCRFCSV 145 
Human  LRNLNLHTVCEEARCPNIGECWGGGEYATATATIMLMGDTCTRGCRFCSV 146 
Drosophila MRELKLSTVCEEARCPNIGECWGGGEHGTQTATIMLMGDTCTRGCRFCSV 146 
  :*:*.* *******************:.* ******************** 
 
Mouse  KTARNPPPLDANEPDNTAKAIAEWGLDYVVLTSVDRDDVADGGAEHIAKT 195 
Rattus KTARNPPPLDPSEPDNTARAIAEWGLDYVVLTSVDRDDVVDGGAEHIAKT 195 
Human  KTARNPPPLDASEPYNTAKAIAEWGLDYVVLTSVDRDDMPDGGAEHIAKT 196 
Drosophila KTARKPPPLDVNEPVNTATAIASWGLDYIVLTSVDRDDLPDGGSEHIAET 196 
  ****:***** .** *** ***.*****:*********: ***:****:* 
 
Mouse  VSCLKERNPKILVECLTPDFRGDLRAVEKVALSGLDVYAHNVETVPELQR 245 
Rattus VSCLKERNPKILVECLTPDFRGDLRAVEKVALSGLDVYAHNVETVPELQR 245 
Human  VSYLKERNPKILVECLTPDFRGDLKAIEKVALSGLDVYAHNVETVPELQS 246 
Drosophila VREIKARNSNIFVECLVPDFRGNLECVKTIANSGLDVYAHNIETVEKLTP 246 
  *  :* **.:*:****.*****:*..::.:* *********:*** :*   
 
Mouse  KVRDPRANFDQSLRVLRHAKEVQPDVVSKTSIMLGLGETDEQVYATLKAL 295 
Rattus KVRDPRANFDQSLRVLKHAKEVQPDVVSKTSIMLGLGETDEQVYATMKAL 295 
Human  KVRDPRANFDQSLRVLKHAKKVQPDVISKTSIMLGLGENDEQVYATMKAL 296 
Drosophila YVRDRRAHYRQTLQVLTEAKRFNPNLITKSSIMLGLGETDEEIENTLKDL 296 
  *** **:: *:*:** .**..:*::::*:********.**::  *:* * 
 
Mouse  RAADVDCLTLGQYMQPTKRHLKVEEYVTPEKFKYWEKVGNELGFLYTASG 345 
Rattus RAADVDCLTLGQYMQPTKRHLKVEEYVTPEKFKYWEEVGNELGFHYTASG 345 
Human  READVDCLTLGQYMQPTRRHLKVEEYITPEKFKYWEKVGNELGFHYTASG 346 
Drosophila REAGVDCVTLGQYMQPTNKHLKVIEYVTPEKFKHWEERGNELGFLYTASG 346 
  * *.***:*********.:**** **:******:**: ****** ***** 
 
Mouse  PLVRSSYKAGEFFLKNLVARRKTKASKV------ 373 
Rattus PLVRSSYKAGEFFLKNLVAKRKTKVSKV------ 373 
Human  PLVRSSYKAGEFFLKNLVAKRKTKDL-------- 372 
Drosophila PLVRSSYKAGEFFITSILENRKKRQNDTEVPKKQ 380 
  *************:..:: .**.:          
 
Figure 3-21: CLUSTALW 2.0.3 multiple sequence alignment for LIAS 
Overall LIAS showed a poor conservation among species through evolution. The highest similarity for 
LIAS was found between Rat and Mouse with a score of 95. Human LIAS had the highest similarity to 
Mouse and Rat with a score of 90 and 91 respectively.  Other species have a poor similarity to human  
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3.4.1.2. Ribosomal Protein L9 CLUSTALW 2.0.3 multiple sequence alignment 
 
RPL9 was found to be highly conserved. Homo sapiens (Human), Pan troglodytes 
(Chimpanzee) and Canis lupus (Timber Wolf) were found to be 100 % identical. The 
mouse (Mus musculus) amino acid sequence was found to be 98 % identical to human 
RPL9 amino acid sequence. Rat (Rattus norvegicus) amino acid sequence was discovered 
to be 93 % identical to human RPL9 sequence and this is due to the longer rat amino acid 
sequence, 17 amino acids longer.  
 
Sequence 1: gi|15431303|ref|NP_000652.2|     192 aa (Homo sapiens) 
Sequence 2: gi|114593631|ref|XP_001141738.   192 aa (Pan troglodytes) 
Sequence 3: gi|57048082|ref|XP_536256.1|     192 aa (Canis familiaris) 
Sequence 4: gi|119904384|ref|XP_001256310.   192 aa (Bos taurus) 
Sequence 5: gi|149249821|ref|XP_001474169.   192 aa (Mus musculus) 
Sequence 6: gi|109503459|ref|XP_224924.3|    209 aa (Rattus norvegicus) 
 
Pair-wise alignment 
 
Sequences (1:2) Aligned. Score:  100 
Sequences (1:3) Aligned. Score:  100 
Sequences (1:4) Aligned. Score:  98 
Sequences (1:5) Aligned. Score:  98 
Sequences (1:6) Aligned. Score:  93 
Sequences (2:3) Aligned. Score:  100 
Sequences (2:4) Aligned. Score:  98 
Sequences (2:5) Aligned. Score:  98 
Sequences (2:6) Aligned. Score:  93 
Sequences (3:4) Aligned. Score:  98 
Sequences (3:5) Aligned. Score:  98 
Sequences (3:6) Aligned. Score:  93 
Sequences (4:5) Aligned. Score:  97 
Sequences (4:6) Aligned. Score:  92 
Sequences (5:6) Aligned. Score:  93 
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 Human  -----------------MKTILSNQTVDIPENVDITLKGRTVIVKGPRGT 33  
Bos   -----------------MKTILSNQTVDIPENVDINLKGRTVIVKGPRGT 33 
Pan  -----------------MKTILSNQTVDIPENVDITLKGRTVIVKGPRGT 33 
Canis  -----------------MKTILSNQTVDIPENVDITLKGRTVIVKGPRGT 33 
Mouse  -----------------MKTILSNQTVDIPENVDITLKGRTVIVKGPRGT 33 
Rattus MVDADSILAFFVPSTARKKTILSNQTVDIPENVDITLKGRTAIVEGPRGT 50 
                    *****************.*****.**:***** 
 
Human  LRRDFNHINVELSLLGKKKKRLRVDKWWGNRKELATVRTICSHVQNMIKG 83 
Bos   LRRDFNHINVELSLLGKKKKRLRVDKWWGNRKELATVLTICSHVQNMIKG 83 
Pan  LRRDFNHINVELSLLGKKKKRLRVDKWWGNRKELATVRTICSHVQNMIKG 83 
Canis  LRRDFNHINVELSLLGKKKKRLRVDKWWGNRKELATVRTICSHVQNMIKG 83 
Mouse  LRRDFNHINVELSLLGKKKKRLRVDKWWGNRKELVTVRTICSHVQNMIKG 83 
Rattus LRRDFNHINVELSLLGKKEKRLRVDKWWGNGKELATVRTICSHVQNVIKG 100 
  ******************:*********** ***.** ********:*** 
 
Human  VTLGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVRMRPGVA 133  
Bos   VTLGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVRMRPGVA 133 
Pan  VTLGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVRMRPGVA 133 
Canis  VTLGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVRMRPGVA 133 
Mouse  VTLGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVRMRTGVA 133 
Rattus VTLGFCYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRRVWMRTNVA 150 
  ***** ************************************* **..** 
 
Human  CSVSQAQKDELILEGNDIELVSNSAALIQQATTVKNKDIRKFLDGIYVSE 183  
Bos   CSVSQAQKDELILEGNDIELVSNSAALIQQATTVKNKDIRKFLDGIYVSE 183 
Pan  CSVSQAQKDELILEGNDIELVSNSAALIQQATTVKNKDIRKFLDGIYVSE 183 
Canis  CSVSQAQKDELILEGNDIELVSNSAALIQQATTVKNKDIRKFLDGIYVSE 183 
Mouse  CFVSQAQKDELILEGNDIELVSNSAALIQQATTVKNKDIRKFLDGIYVSE 183 
Rattus CSVSQAQKDELILEGNDIELVSNSAALIQQGTTVKNKDISKFLDGIYVSE 200 
  * ****************************.******** ********** 
 
Human  KGTVQQADE 192  
Bos   KGTVQQADE 192 
Pan  KGTVQQADE 192 
Canis  KGTVQQADE 192 
Mouse  KGTVQQADE 192 
Rattus KGTVQQADE 209 
  ********* 
 
 
Figure 3-22: CLUSTALW 2.0.3 multiple sequence alignment for RPL9 
RPL9 showed a strong conservation through evolution. A 100 % similarity was found between Human, 
Chimpanzee and Timber Wolf.  
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3.4.2. Bioinformatics gene Interaction  
BONDplus database was used to find any reported interactions of LIAS and RPL9 with 
other genes or gene products. No interaction of LIAS with other genes was reported thus 
far. Li et.al., 2003 reported interaction of c-myc, max, polII and TafII250 with RPL9 
promoter region. The ratio of expression of RPL9 against c-myc, max and TafII250 was 
found to be 3.56, 3.59 and 4.95 respectively. Among other genes promoter regions 
reported to interact with c-myc were tumour suppressor gene p53, pro-apoptotic Bax and 
anti-apoptotic Bcl2 with a ratio of expression to c-myc of 2.42, 1.16 and 0.77 
respectively.  
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Summary 
Biologists estimate that there are about 5 to 100 million species of organisms living on 
Earth today. Evidence from morphological, biochemical, and gene sequence data 
suggests that all organisms on Earth are genetically related. RPL9 was found to be highly 
conserved, and this could be because of its function in protein synthesis. NCBI was used 
to obtain the gene homologues for human RPL9 and LIAS. The protein sequences for 
genes with highest similarity to human were used to do a multiple sequence alignments 
using CLUSTAL 2.0.3 tool. Homo sapiens (Human), Pan troglodytes (Chimpanzee) and 
Canis lupus (Timber Wolf) were found to be 100 % similar (figure 3-22). Lipoic acid 
synthetase was found to be less conserved through the species. Sequence alignment 
showed a 90%, 91 % and 61 % similarity to Mus musculus (mouse), Rattus norvegicus 
(rat) and Drosophilla respectively (figure 3-21).  
 
No interaction with other genes was reported for LIAS on the BONDplus database. c-
Myc, max, polII, TafII250 were reported to interact with RPL9 promoter region (Li et.al., 
2003) suggesting that the expression of RPL9 is controlled by transcription factor c-myc. 
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4. Discussion 
4.1. Lung cancer 
Lung cancer is the most important leading cause of death due to cancer. Although lung 
cancer has a lower incident rate than other types of cancers (breast, colon, prostate and 
cervical), it is very lethal and the 5 years survival rate is less than 5 %. About 60 % of the 
people diagnosed with lung cancer die within one year and nearly 75 % die within two 
years and the figures have not improved in the past decade (American Cancer Society, 
2006). In South Africa, lung cancer constitutes 6.7% of all cancers in men and 2.8% of all 
cancers in women from all age groups. Breaking down these figures into race groups, the 
coloured and white males combined constitute 42.4% of all male lung cancer cases  and 
black men constitute 55% of lung cancer cases which is the highest incidence rates 
among the male population (Sitas, et al., 1998).   
 
Most cytotoxic drugs kill tumour cells by apoptosis. Defects in apoptosis signaling have a 
great contribution to resistance of tumour cells to chemotherapy. One of the characteristic 
features for lung cancer is resistance to apoptosis which suggest that the sensitization to 
apoptosis of lung tumour cells is very crucial in the attempt to treat lung cancer 
(Nachmais et al., 2004). Discovery of anti-apoptotic and pro-apoptotic genes is very 
essential in the discovery of novel therapeutic drugs directed at eradicating tumour cells 
by targeting apoptosis not only in lung cancer but cancer in general.  
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4.2. In Situ Hybridization 
In Situ Hybridization was used to localize as well as to assess the expression of RPL9 and 
LIAS at tissue level in normal and lung cancer using anti-sense probes. Down or up-
regulation of RPL9 and LIAS was determined by comparing the intensity of the labeling 
by both colorimetric and fluorescence detection. RPL9 localised in the cytoplasm of both 
normal and cancerous tissue but the expression was higher in the cancer than the normal. 
The expression increased with the progression of the cancer from poor to well 
differentiated of lung adenocarcinoma and squamous cell lung carcinoma. The expression 
was the highest in small cell lung carcinoma followed by adenocarcinoma and then 
squamous cell lung carcinoma. RPL9 was least expressed in large cell carcinoma. LIAS 
also localised in the cytoplasm. Literature indicates that LIAS is expressed in the 
mitochondrion which is located in the cytoplasm. This would have been observed if a 
high resolution and magnification microscope such as an electron microscope was used. 
Using the intensity of the labelling to quantify the expression, LIAS expression increased 
with the progression of squamous cell lung carcinoma and adenocarcinoma from poor to 
well differentiated. However the expression of LIAS was the highest in adenorcarcinoma, 
followed by squamous cell carcinoma and the lowest in small cell carcinoma. The overall 
expression of RPL9 is relatively higher than LIAS in lung normal tissue and lung cancer.   
Over-expression and loss of function of a number of genes such as tumour suppressor 
genes (p53 and Rb) and proto-oncogenes (c-myc) has been associated with different types 
of cancer including lung cancer (Kohno and Yokota, 1999; Sherr and McCormick, 2002).  
Tumour cells over-express these genes in the attempt to induce apoptosis with no success. 
This could mainly be due to the fact that apoptosis is a molecular mechanism that involve 
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a couple of genes among which some are usually mutated in cancer. But the gene 
products will still accumulate in the cell.  
 
Over-expression of RPL9 and LIAS further suggests that either RPL9 or LIAS or both 
could be directly or indirectly associated with apoptosis. Quantitative Real-time PCR and 
Bioinformatics tools were used for further analyses.   
 
4.3. Real Time Polymerase Chain Reaction 
Real Time PCR is a technique used in gene expression analyses. It uses the principle of 
polymerase chain reaction but unlike the conventional method which determines the 
amount of product formed at the end of the reaction, Real Time polymerase chain 
reaction measures the amount of product real time that is after every cycle. With good set 
of primers and under optimum conditions, polymerase chain reaction is exponential, that 
is the product doubles after every cycle. With modern technology that allows 
measurement of product after every cycle this has proved to be a very useful tool in gene 
expression analyses. Different indicators are included in the reaction depending on the 
objective of the experiment. The most common are DNA binding fluorescence dyes such 
as SYBR green. The dye binds exclusively to double stranded DNA and fluoresces at a 
specific wavelength. 
Expression of RPL9 and LIAS was relatively quantified in lung cancer using lung normal 
fibroblast as a reference. Lung adenocarcinoma A549 and lung normal MRC5 fibroblast 
cell lines were used. The choice of A549 as a representative for lung cancer was 
motivated by the fact that, lung adenocarcinoma is the most common type of all lung 
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cancers, mainly because of high prevalence of tobacco smoking. RNA extracted from 
A549 and MRC5 cultured cell lines was used to synthesize cDNA by reverse 
transcription using oligo-(dT)15 primers. cDNA was quantified and the same amount for 
cancer and normal used for real time PCR using gene specific primers. The efficiency of 
RPL9 primer was optimized to 98 % and 97 % for LIAS by using standard curves. 
Specificity of the reaction for both genes was determined and optimized by melting 
curves. Non-specificity and contamination of primers can be demonstrated by multiple 
picks on the melting curve with a different melting temperature to that of the expected 
product. Because SYBR binds to any double stranded DNA, designing primers that do 
not form dimers is very crucial. Because of the high sensitivity of this technique, primer 
dimers can be detected even at very low quantities and this can be demonstrated as picks 
with low melting temperature because of their relatively smaller size. Using the same 
amount of cDNA and running the reactions at optimum conditions ensures that any 
variation in the amount of the product formed signified the difference in expression level 
of the gene in lung cancer relative to the normal lung.  
Taking the ratio of the threshold cycle of the test (cancer) to that of the calibrator 
(normal) the expression level of RPL9 was found to be 8-fold up-regulated in lung 
adenocarcinoma relative to the normal counterpart. These results imply that RPL9 is 
expressed in lung adenocarcinoma 8 times more than in the normal lung. LIAS was found 
to be 4-fold up-regulated in lung cancer relative to normal lung.  
The relatively high difference in expression level of RPL9 and LIAS in adenocarcinoma 
to normal lung, together with the resistance to apoptosis of CHO cell line with mutated 
RPL9 and LIAS suggests that one of the two genes or both may be very crucial in 
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mammalian apoptotic pathway. As it is well known that failure to undergo apoptosis by 
cells can lead to development of cancer, any molecular maker that can assist in early 
detection of cancer is very important. These can also lead to improved treatment of not 
only lung cancer but also other types of cancer.  
 
4.4. Bioinformatics 
BONDplus database was used to search for any reported interaction discoveries of RPL9 
and LIAS. Gene IDs were obtained from NCBI and no interaction discoveries for LIAS 
were reported. For RPL9, the search returned a discovery by Li et al (2003) that was 
aiming at determining the transcriptional regulatory role of c-myc. The study reported the 
interaction of c-Myc, Max, PolII and TAFII250 proteins with RPL9 promoter region in 
the Daudi cells. Daudi cells, is an established cell line originally derived from Burkitt’s 
lymphoma patients. These cells express a high level of c-myc and have been used 
extensively as an experimental system to study the role of c-myc.  
The c-myc gene is a proto-oncogene that was discovered over 20 years ago as the cellular 
homolog of the retroviral v-myc oncogene (Bishop, 1982; Bister and Jansen 1986). Later 
on the c-myc proto-oncogene was found to be activated in various animal and human 
tumours (Cole, 1986). c-Myc protein contains a transactivation domain within its N-
terminal 140 aa (Kato et al., 1990). The c-myc binds to and transactivates through 
consensus 5’-CACGTG-3’ sequences (Dang, 1999). Major roles of c-myc include 
regulation of the cell cycle, differentiation and apoptosis. The search for c-myc partner 
resulted in the discovery of Max protein. Max (myc associated factor X) is a transcription 
factor that functions as a homodimer or heterodime with Mad, Mxi1 and Myc. In contrast 
   111
 
to Myc, Max does not contain a transcription protein. Myc/Max heterodimewrs bind to 
target sites to transactivate genes via the myc transactivation domain. Max homodimers 
are thought to counter the function of the Myc/Max heterodimers through competitive 
binding to target DNA sites.  
A study on the 32D.3 myeloid progenitor cell line further support the role of c-myc in 
apoptosis. The cell line is dependent on interleukin-3 (IL-3) for myc expression and 
growth showed the continuous drive of cells into S-phase and accelerated rate of 
apoptosis under the enforced c-myc expression and in the absence of IL-3. Serum 
deprived Rat1 fibroblasts overexpressing c-myc undergo dramatic apoptosis that is 
dependent on the wild type p53. The regions of c-myc required for transcriptional 
regulation and cellular transformation are also required for serum deprived-induced 
apoptosis. Therefore it is summarized that c-myc protein affects the transcription of genes 
that participate in apoptosis and because of frequent association of c-myc oncogene with 
human malignancies, identification of c-myc interacting genes might help in the fight 
against human malignancies.          
PNAS supporting data for the study by Li et al., 2003 showed an up-regulation of RPL9 
and other genes that were up-regulated is apoptotic genes p53 and Bax. An anti-apoptotic 
gene Bcl-2 was down-regulated. The ratio of expression of RPL9 was relatively higher 
than most well characterized genes. The high expression of RPL9 was also discovered by 
quantitative real time PCR and in situ hybridization.  
CLUSTALW 2.0.3 Multiple sequence alignment was employed to further analyse the 
biological role of RPL9 and LIAS. The results showed a less conservation of LIAS amino 
acid through evolution. The highest similarity was obtained between Human (Homo 
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sapiens) and Rat (Rattus norvegicus) LIAS with a similarity score of 91 %. Contrary to 
LIAS, RPL9 has been highly conserved through evolution. Human (Homo sapiens) RPL9 
amino acid sequence was found to be 100 % identical to Pan troglodytes (Chimpanzee) 
and Canis lupus (Timber Wolf) and 98 % identical to the mouse (Mus musculus) amino 
acid sequence. The high conservation of RPL9 through evolution could be an indication 
of its biological function in apoptosis. The same pattern of conservation is observed 
among other crucial genes such as p53. 
Paul et al (Paul et al., 1995) reported high level of antigenic activity in ribosomes 
isolated from mouse UV induced 6132A PRO tumour cells. Reintroduction of the lost 
wild type L9 allele into 6132A-PRO variant suppressed the growth of tumour cells in 
vivo. This study support the preliminary finding by Prof D.J.G Rees that discovered 
resistance to apoptosis by the CHO cell line following promoter trap mutagenesis, 
resulting in mutation in LIAS and RPL9.  
High expression of RPL9 in cancer cell line and tissue section coupled with high 
conservation through evolution, as well as supporting literature showing an interaction of 
RPL9 with c-myc and antigen activity from cell lines with mutations on the RPL9 allele 
strongly suggest that RPL9 may play a crucial role in apoptosis as a pro-apototic gene.  
 
4.5. TUNEL 
One of the characteristics of apoptosis is the degradation of DNA after the activation 
endonucleases. This DNA cleavage leads to strand breaks within the DNA. 
The TUNEL method identifies apoptotic cells in situ by using terminal deoxynucleotidyl 
transferase (TdT) to transfer biotin-dUTP to these strand breaks of cleaved DNA. The 
   113
 
biotin-labeled cleavage sites are then detected by reaction with HRP conjugated 
streptavidin and visualized by DAB showing brown color. 
Fragmentation of the DNA was observed in the cytoplasm. The highest fragmentation is 
the highest in adenocarcinoma and by comparing the results obtained from In situ 
Hybridization and Real Time PCR it can be concluded that apoptosis occurs in the same 
regions and the same pattern as the expression level of RPL9 mRNA. Localisation of 
RPL9 mRNA was the highest in adenocarcinoma, followed by squamous cell carcinoma 
and then large cell carcinoma. This association is also the same with LIAS expression. 
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5. Conclusion 
In situ hybridization showed localization of RPL9 and LIAS in the cytoplasm of both 
normal and cancerous lung tissue sections. The intensity of localization was greater in 
cancer than in normal tissue. The expression of RPL9 was greater in small cell lung 
carcinoma, followed by adenocarcinoma, squamous cell lung carcinoma and then large 
cell lung carcinoma. However the expression of LIAS was the highest in 
adenorcarcinoma, followed by squamous cell carcinoma and the lowest in small cell 
carcinoma. The overall expression of RPL9 was relatively higher than LIAS. Quantitative 
real time PCR confirmed the up-regulation of RPL9 and LIAS in lung cancer relative to 
its normal counterpart. It also confirmed the relatively high expression of RPL9 
compared to LIAS. The fragmentation of DNA was measured by TUNEL. The DNA 
fragmentation was observed in the cytoplasm and is the highest in adenocarcinoma. 
Comparing TUNEL and In situ hybridization results, LIAS and RPL9 mRNA localises in 
the cytoplasm which is the side where DNA fragmentation was observed. This pattern 
further serves as an evidence of the involvement of RPL9 and LIAS in apoptosis.  
Bio-informatics tool, CLUSTAL 2.0.3 revealed that LIAS is less conserved through 
evolution. A high conservation was revealed with RPL9. Human RPL9 was found to be 
100 % similar to that of Timber Wolf and Chimpanzee and 98 % to mouse L9. 
BONDplus database reported an interaction of c-myc proto-oncogene, max, polII and 
TAFII250 transcription factor with RPL9 promoter region. Major roles of c-myc and 
TAFII250 include regulation of the cell cycle, differentiation and induction of apoptosis. 
The ratio of expression of RPL9 to c-myc was high which indicates a strong interaction. 
This strongly suggests that RPL9 is involved in the induction of apoptosis 
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All these discoveries coupled with resistance to apoptosis of CHO cell line in which 
RPL9 and LIAS were found to be mutated following promoter-trap mutagenesis, strongly 
suggests that RPL9 might be playing a role in cell cycle and apoptosis and the elevated 
expression of RPL9 can be used a molecular marker for cancer diagnosis.  
This study showed preliminary results presenting a vital direction to future studies to 
investigate the molecular functions of these two genes.  
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Appendix 1: Reagents and Solutions 
 
 
Tfb1 
30nM KAc 
(Fluka Chemie GmbH, Sigma-Aldrich Chemie, GmbH, 
Steinheim, Switzerland) 
50 mM MnCL2 
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalie GmbH, 
Seelze) 
10mM CaCl2 
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalie GmbH, 
Seelze) 
100mM MnCl2 
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalie GmbH, 
Seelze) 
15% (v/v) Glycerol 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
Solution was sterilized by filtration 
 
 
Tfb2 
10 mM MOPS, pH 7.0 
(Fluka Chemie GmbH, Sigma-Aldrich Chemie, GmbH, 
Steinheim, Switzerland) 
75 mM CaCl2  
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalie GmbH, 
Seelze) 
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10 mM KCI  
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalie GmbH, 
Seelze) 
15 % (v/v) Glycerol 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
Solution sterilized by filtration 
 
 
TYM Broth 
2.0 % Bacto-Tryptone 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
0.5 % Bacto-Yeast Extract 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
0.1 M NaCl 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
10 mM MgCl2 
(Merck Chemicals (Pty) Ltd, Gauteng, South Africa) 
pH to 7.0 with NaOH. Autoclave 
1.0 M NaOH Dissolve 36.9 g NaOH (Merck Chemicals (Pty) Ltd, 
Gauteng, South Africa) 
 in 100 ml dH2O 
70 % Ethanol 70 ml 100 % Ethanol and make up 100 ml with dH2O 
0.1 % (v/v) DEPC H2O 1 ml DEPC (Sigma-Aldrich Chemie GmbH, Steinheim, 
Switzerland) in 1 L dH2O 
Shake a 37°C overnight and autoclave 
 100 mM Tris 
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10 X Reaction Buffer, pH 
8.3 
500mM KCl 
 
 
dNTP Mix 
10 mM dATP 
10 mM dCTP 
10 mM dTTP 
10 mM dGTP 
Luria Broth 1 % Bacto-Tryptone (w/w) 
0.5 % Bacto-Yeast Extract (w/w) 
1 % NaCl (w/w) 
Bring to 1 litre with dH2O 
Agar plates 14g Nutrient Agar (w/w) 
500 ml distilled water 
Boil to dissolve and autoclave 
Pour agar in Petri dishes, wrap in foil and store at 4°C 
100 mg/ ml Ampicillin Dissolve 0.1g Ampicillin (Roche Diagnostics GmbH, 
Mannehein, Germany) in 1 ml sdH2O  
100 µg/ L Ampicillin  
Agar Plates 
Dissolve 50 µl 100 mg/ ml Ampicillin to slightly cooled 
Luria Agar and swirl to mix. Pour agar in Petri dishes and 
store at 4 °C   
4 % PFA  Dissolve 2.5 g PFA (Merck Chemicals (Pty) Ltd, Gauteng, 
South Africa) in 25 ml 200 mM Phosphate Buffer by slow 
heating to 60 °C until solution becomes clear  
200 mM Phosphate  4.3 g Disodium Hydrogen-Orthophosphate (Na2HPO4) 
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Buffer, pH 7.4 Anhydrous (Merck Chemicals (Pty) Ltd, Gauteng, South 
Africa)  
3.1 g Sodium Dihydrogen Phosphate (NaH2PO4) (Riedel-
de-Haën, Sigma-Aldrich Laborchemikalie GmbH, Seelze)  
Add 250 ml DEPC-treated H2O and autoclave 
0.1 M HCl Dilute 10 ml 9M (32 % HCI (v/v) with 990 ml DEPC-
treated H2O) 
10 X TBS 50 ml 1 M Tris, pH 7.5 
30 ml 5 M NaCl  
Make up to 1 L with DEPC Treated H2O 
1 M Tris, pH 7.5 Dissolve 6.1 g Tris in 50 ml dH2O  
Adjust pH to 7.5 with 1 M HCl. 
Autoclave 
5 M NaCl Dissolve 73.05 g NaCl in 250 ml dH2O.  
Autoclave 
0.5 % Acetic Anhydride Add 0.25 ml 100% Acetic Anhydride (v/v) (Merck 
Chemicals (Pty) Ltd, Gauteng, South Africa) to 5 ml 1 M 
Tris, pH 7.5 and make up to 50 ml with DEPC treated H2O  
20 X SSC Dissolve 175.3 g NaCl, 88.2 g Tri-Sodium Citrate (Merck 
Chemicals (Pty) Ltd, Gauteng, South Africa) in 800 ml 
DEPC-treated H2O. Adjust to pH 7.0 with 0.1 M HCl and 
make up to 1 L with DEPC-treated H2O  
40 % Dextran (v/v) Add 40 g Dextran Sulphate Sodium Salt (Sigma-Aldrich, 
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Germany) to 70 ml DEPC-treated H2O. Dissolve by heating 
at 68 °C for 3-4 hours. Make up to 100 ml with DEPC-
treated H2O. Store at 4 °C 
10 % SDS Dissolve 10 g SDS (Roche Diagnostics, Germany) in 100 
ml DEPC-treated H2O 
50 % Formamide  Add 12.5 ml Formamide to 12.5 ml DEPC-treated H2O 
0.8 % (w/v) agarose gel 
 
Dissolve 0.8 g agarose in 100ml 1 X TBE buffer. Allow to 
cool to 50 °C and add 1 µl of 100 µl/ ml ethidium bromide. 
Allowed to set in a gel-casting tray 
37 % (v/v) formaldehyde 
 
Add 3.7 ml 100 % Formaldehyde (Riedel-de-Haën, Sigma 
Aldrich Laborchemikalien GmbH, Seelze) to 6.3 ml DEPC-
treated H2O 
10 X TBE buffer 
 
108 g Tris 
55 g Boric acid  
9.3 g EDTA (Saarchem Merck, Gauteng, South Africa) 
Dissolve and make final volume to 1l, adjust pH to 8.3 
10 X TE buffer 
 
12.11 g Tris-Cl (Sigma, Steinheim, Germany) 
5.72 g EDTA (Saarchem Merck, Gauteng, South Africa) 
700 ml distilled water 
Adjust pH to 7.5, make final volume to 1 l, autoclave 
1 % (w/v) formaldehyde 
agarose gel 
Dissolve 1 g agarose in 10 X MOPS and 84.6 ml DEPC-
treated H2O. 
Allow the gel to cool to 50 °C prior to addition of 5.4 ml 37 
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% (v/v) formaldehyde and 4 µl of 100 µg/ml ethidium 
bromide 
Formaldehyde Gel 
Loading Buffer 
720 µl Formamide 
160 µl 10 X MOPS Buffer 
260 µl 37 % Formaldehyde (v/v) 
100 µl DEPC-treated H2O 
10 mg/ ml Ethidium Bromide 
80 µl Bromophenol Blue (Riedel-de-Haën, Sigma Aldrich 
Laborchemikalien GmbH, Seelze)  
10 X MOPS 41.86 g MOPS 
3.72 g EDTA  
4.1 g Sodium Acetate 
Make up to 1 l with distilled water, wrap bottle in foil 
4 M LiCl Dissolve 8.478 g LiCl (Sigma Aldrich, Germany) in 50 ml 
sdH2O. 
TNB 2 ml Maleic Acid 
2.5 ml Blocking buffer 
45 ml 1 X TBS 
10 X PBS Dissolve in 800 ml of sdH2O: 
8 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 · 12H2O and 
0.24 g KH2PO4. 
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Adjust the pH to 7.4 with HCl. 
Add sdH2O to 1 L 
0.5 M EDTA, pH 8.0 Dissolve 18.62 g EDTA (Merck Chemicals (Pty) Ltd, 
Gauteng, South Africa) in 50 ml sdH2O. Adjust pH with 1 
M NaOH until pH 8.0 and make up to 100 ml with DEPC 
H2O 
10 X Maleic Acid 
(Roche Diagnostics, 
Germany) 
0.1 M Tris-HCl 
0.15 M NaCl 
Adjust to pH 7.5 with NaOH 
20 X TBS-Tween 5 ml Tween 20 (Sigma –Aldrich, Germany) to the final 
volume of 1L with 1 X TBS 
1 X Blocking buffer 5 ml 10 X Maleic Acid 
5 ml 10 X blocking buffer 
40 ml Sterile distilled water 
1 X Detection buffer 5 ml 10 X detection duffer 
45 ml sterile distilled water 
 
